ISPOR 20th Annual European Congress

4-8 NOVEMBER 2017
SCOTTISH EVENT CAMPUS (SEC)
GLASGOW, SCOTLAND

The Evolution of Value in Health Care

PROGRAM AND SCHEDULE OF EVENTS

#ISPORGlasgow
WI-FI NETWORK: ISPORGLASGOW // PASSWORD: IQVIA2017

www.ispor.org
About ISPOR

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is the leading global scientific and educational organization for health economics and outcomes research (HEOR). ISPOR's mission is to promote HEOR excellence to improve decision making for health globally.

ISPOR Strategic Pillars

Scientific and Research Excellence
ISPOR is committed to strengthening the integrity, advancement, understanding, and use of health economics and outcomes research among researchers, health technology developers and assessors, regulators, health economists, health care policy makers, payers, providers, patients, populations, and society.

Member Engagement
Through its worldwide membership and stakeholder groups, ISPOR has access to the ideas, knowledge, skills, and experiences that enable achievement of its mission. ISPOR offers membership benefits that are valued and essential in members' professional growth.

Organizational Values
Knowledge and skill building are at the core of the ISPOR mission. ISPOR will lead efforts to strengthen and expand capabilities in health economics and outcomes research.

Education and Training
ISPOR will be a valued and reliable resource for translating knowledge into practice for decision makers and stakeholders, who include members, providers, payers, patients, professional societies, foundations, health authorities, the media, and others.

Communication and Collaboration

ISPOR Membership

ISPOR has a 20+ year legacy as an unbiased organization of more than 20,000 individual and chapter members. ISPOR promotes HEOR excellence through its:

- Scientific meetings and conferences
- MEDLINE®/PubMed-indexed journals
- Educational programs
- Roundtables, councils, and collaborative alliances
- Online tools
- Scientific and health policy groups
- Regional consortia, networks, and chapters
- Dialogue with payers and health care decision makers

Additional information on ISPOR and membership benefits can be found at www.ispor.org.

© 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Table of Contents

Congress Program Committee . . . . . . . . . . 5
Event Sponsors . . . . . . . . . . . . . . . . . . . . . . . . . 6
Plenary Sessions . . . . . . . . . . . . . . . . . . . . . . . . 7
Schedule of Events . . . . . . . . . . . . . . . . . . . . . . . . . 9
  Saturday, 4 November . . . . . . . . . . . . . . . . . . . 9
  Sunday, 5 November . . . . . . . . . . . . . . . . . . . . 12
  Monday, 6 November . . . . . . . . . . . . . . . . . . . 15
  Tuesday, 7 November . . . . . . . . . . . . . . . . . . . 21
  Wednesday, 8 November . . . . . . . . . . . . . . . . . . 27
Invitational Group Meetings . . . . . . . . . . . . . . . . 31
Poster Overview . . . . . . . . . . . . . . . . . . . . . . . . . 34
Exhibit Program Overview . . . . . . . . . . . . . . . . . . 35
Exhibitor Listing . . . . . . . . . . . . . . . . . . . . . . . . . 36
Exhibit/Poster Hall Floor Plan . . . . . . . . . . . . . . . 37
Key Congress Information . . . . . . . . . . . . . . . . . . 39
Conference Rooms Floor Plan . . . . . . . . . . . . . . . 40
We are advancing peri- and post-approval research.

38 Presentations at ISPOR GLASGOW

2 Short Courses 1 Forum
2 Workshops 1 Podium
3 Issue Panels 29 Posters

30+ Years of Experience
Epidemiology · Health Economics · Interventional Studies
Real-World Evidence · Patient-Centered Research · Evalytica®
Pragmatic / Adaptive Trials · Modeling and Meta Analysis
Market Access · Medical Writing

www.evidera.com  www.evalytica.com
Congress Program Committee

ISPOR thanks the Congress Program Committee for its contributions in developing the scientific community’s leading HEOR program.

PROGRAM COMMITTEE CO-CHAIRS
Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK
Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands

RESEARCH REVIEW COMMITTEE CO-CHAIRS
Margreet G. Franken, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands
Rok Hren, PhD, University of Ljubljana, Ljubljana, Slovenia
Andrea Manca, University of York, Heslington, York, UK
Ursula Rochau, MD, MSc, UMIT - University for Health Sciences, Medical Informatics and Technology, Tirol, Austria

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS
René Allard, PhD, Grünenthal GmbH, Aachen, Germany
Jan Geissler, Leukemia Patient Advocates Foundation, Patvocates, and European Patients’ Academy (EUPATI), Munich, Germany
Camilla Palmhoj Nielsen, PhD, DEFACTUM, Aarhus N, Denmark

WORKSHOP REVIEW COMMITTEE CO-CHAIRS
Raquel Aguia-Ibañez, MSc, MSD, Hoddesdon, UK
Martin Scott, MSc, Numerus Ltd., Tübingen, Germany
Allan Wailoo, PhD, University of Sheffield and NICE Decision Support Unit, Sheffield, UK
# Thank You to Our Event Sponsors

## Platinum Level Sponsors

| CHEORS  
|---|
| Healthcore  
| TRUVEN  
| Health Analytics  
| an IBM Company  
| pharmerit\  
| international  
| IMS Health & Quintiles are now IQVIA |

## Gold Level Sponsors

| Evidera  
|---|
| PRECISION  
| FOR VALUE  
| PART OF PRECISION VALUE & HEALTH |

## Silver Level Sponsors

| BASECASE  
|---|
| HEOR  
| COVANCE MARKET ACCESS  
| Experience Forward Thinking  
| COVANCE  
| INGRESS  
| for technologies in health |

## Bronze Level Sponsors

| PHMR  
|---|
| SIRIUS  
| market access  
| PEOPLE MAKE GLASGOW |

---

6 | #ISPORGlasgow
FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?
There now is a wide consensus that health care products and services should be priced in relation to the additional value they produce. While cost-effectiveness analysis explicitly assumes allocation of resources based on added societal value, practitioners and health care policy makers in European institutions now increasingly promote value-based health care (VBHC) as a more holistic, patient-centered understanding of value. Although VBHC seems well aligned with cost-effectiveness analysis, there are several fundamental differences. Where VBHC is embraced by health care practitioners and hospital administrators because of its focus on patient value over the entire care pathways instead of single interventions, it lacks an operational definition of value in relation to cost. Another difference is that outcomes in VBHC are disease-specific, which implies they cannot be used for societal resource allocation decisions. This plenary session will therefore introduce VBHC in more general terms from a clinical and hospital perspective.

Moderator: Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands
Speakers: Peter Naredi, University of Gothenburg and European CanCer Organization (ECCO), Brussels, Belgium; Luke Slawomirski, Organisation for Economic Co-operation and Development (OECD), Paris, France; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and European Society for Medical Oncology (ESMO), Uppsala, Sweden; Jason Arora, MD, MPH, Medtronic, Watford, UK

SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?
Health technology assessment (HTA) processes vary across jurisdictions. Some countries are early adopters and include a formal economic evaluation (Canada, United Kingdom, Australia, Sweden, The Netherlands); others have a less arduous approach without formal QALY-type assessment (France, Spain, Italy), and still others prefer to reference HTAs performed elsewhere (Romania, Bulgaria). In addition, bodies such as EUnetHTA offer the potential to streamline processes by enabling information sharing and structured collaboration between jurisdictions. However, how cost-effective are the HTA processes? What is the value for money of the HTA activities? Is there a “perfect HTA process” that can serve as the benchmark for other countries to adopt or adapt? This plenary session will explore how HTA processes (or lack of HTA processes) might be compared and evaluated and the speakers will present different perspectives on evaluating the value of HTA processes.

Moderator: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK
Speakers: Susan Guthrie, PhD, MSci, Rand Europe, Cambridge, UK; Nicola Allen, PhD, Precision for Value, London, UK; Zoe Garrett, MPhil, MRes, National Institute for Health and Care Excellence (NICE) and EUnetHTA, Manchester, UK

THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC
As the rate of medical innovation accelerates, competing demands from various stakeholders put unprecedented pressure on health systems to deliver high-value medical care. Most health systems claim to link coverage decisions to the value for money afforded by specific treatments, but their approaches to valuation differ. Many countries, such as the United Kingdom, have historically relied on traditional cost-effectiveness analysis using the cost-per-QALY metric to guide coverage decisions. Other countries like France and Germany never adopted the uncertain place of cost-utility analysis from an industrial, health economics, and patient perspective. However, how cost-effective are the HTA processes? What is the value for money of the HTA activities? Is there a “perfect HTA process” that can serve as the benchmark for other countries to adopt or adapt? This plenary session will explore how HTA processes (or lack of HTA processes) might be compared and evaluated and the speakers will present different perspectives on evaluating the value of HTA processes.

Moderator: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA
Speakers: Mandy Ryan, PhD, MSc, University of Aberdeen, Aberdeen, UK; Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; Jérôme Wittwer, PhD, Bordeaux University, Bordeaux, France
A pharmaceutical company that helps you see what others don’t

The Mundipharma global network of independent associated pharmaceutical companies successfully builds alliances to develop and market medicines.

We are looking for alliance partners developing therapies in pain, respiratory, oncology and biosimilars or new areas of exploration.

Contact us at: businessdevelopment@mundipharma.co.uk
www.mundipharma.com

Mundipharma International Limited proud developers of the BEACON framework

MINT/UNAL - 17017b
August 2017
## Congress Schedule of Events

### SATURDAY, 4 NOVEMBER

**7:00-18:00**  **REGISTRATION HELP DESK HOURS**  **Hall 5**

**8:00-17:00**  **SHORT COURSE FULL DAY**  **(Separate Registration Required)**
**Introduction to Health Economic/Pharmacoeconomic Evaluations**  **Hall 2**

- **Track:** Economic Methods
- **Level:** Introductory  *This course is suitable for those with little or no experience with pharmacoeconomics.*
- **Faculty:** Lieven Annemans, PhD, MSc, Ghent University - Brussels University, Ghent, Belgium

**8:00-12:00**  **SHORT COURSE MORNING SESSION**  **(Separate Registration Required)**
**Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources**  **Lomonad Auditorium (Loch Suite)**

- **Track:** Observational Data Methods
- **Level:** Introductory
- **Faculty:** Linus Jönsson, PhD, MD, MSc, H. Lundbeck A/S, Valby, Denmark; Bradley C. Martin, PharmD, PhD, RPh, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

**Introduction to Patient-Reported Outcomes Assessment**  **Carron (Loch Suite)**

- **Track:** Patient-Reported Outcomes Methods
- **Level:** Introductory  *This is an entry level course which assumes only a passing familiarity with patient-reported outcomes.*
- **Faculty:** Kevin Weinfurt, PhD, Duke Clinical Research Institute, Durham, NC, USA

**Introduction to Modeling**  **Boisdale (Loch Suite)**

- **Track:** Modeling Methods
- **Level:** Introductory  *This course is designed for those with some familiarity with modeling techniques.*
- **Faculty:** Uwe Siebert, MD, MPH, MSc, ScD, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

**Development of Conceptual Models**  **Leven+Morar+Ness (Seminar Suite)**

- **Track:** Modeling Methods
- **Level:** Introductory
- **Faculty:** Neil Hawkins, PhD, University of Glasgow, Glasgow, UK; Mark S. Roberts, MD, MPP, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; Elisabeth Fenwick, PhD, MSc, ICON Health Economics and Epidemiology, Abingdon, UK; Paul Tappenden, PhD, MSc, University of Sheffield, Sheffield, UK; Beth Woods, MSc, University of York, Heslington, York, UK

**Cost-Effectiveness Analysis Alongside Clinical Trials**  **Alsh (Loch Suite)**

- **Track:** Economic Methods
- **Level:** Intermediate  *Familiarity with economic evaluations will be helpful.*
- **Faculty:** Richard J. Willke, PhD, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA; Lotte Steuten, PhD, Hutchinson Institute for Cancer Outcomes Research (HICOR) and University of Washington, Seattle, WA, USA

**Elements of Pharmaceutical / Biotech Pricing**  **Hall 1**

- **Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information
- **Level:** Introductory  *This course is designed for those with limited experience in the area of pharmaceutical pricing and will cover topics within a global context.*
- **Faculty:** Jack M. Mycka, Medical Marketing Economics LLC (MME), Montclair, NJ, USA; Renato Dellamano, PhD, MME Europe & ValueVector (Value Added Business Strategies), Milan, Italy
### SCHEDULE OF EVENTS

**SATURDAY**

ISPOR 20th Annual European Congress
The Evolution of Value in Health Care

---

**Conjoint Analysis – Theory & Methods**

**Dochart (Loch Suite)**

- **Track:** Patient Preference Methods
- **Level:** Intermediate  This course is designed for clinicians, policymakers, researchers, and patient advocates/researchers with some familiarity with conjoint analysis or other stated-preference methods.
- **Faculty:**
  - A. Brett Hauber, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; John F. P. Bridges, PhD, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

---

**10:00-10:15**  **COFFEE BREAK**

Coffee Break Sponsored by Sirius Market Access

---

**12:00-13:00**  **LUNCH**

(Attendees on their own)

---

**13:00-17:00**  **SHORT COURSE AFTERNOON SESSION**

*Separate Registration Required*

#### Introduction to Health Technology Assessment

**Lomond Auditorium (Loch Suite)**

- **Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information
- **Level:** Introductory  This course is suitable for those with little or no experience with HTA.
- **Faculty:**
  - Uwe Siebert, MD, MPH, MSc, ScD, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

#### Meta-Analysis & Systematic Literature Review

**Alsh (Loch Suite)**

- **Track:** Outcomes Research Methods
- **Level:** Intermediate
- **Prereq.:** Previous attendance at the ISPOR short course, “Statistical Methods for Pharmacoeconomics & Outcomes Research,” or equivalent knowledge, is recommended.
- **Faculty:**
  - Olivia Wu, PhD, University of Glasgow, Glasgow, UK; Neil Hawkins, PhD, University of Glasgow, Glasgow, UK

#### Statistical Methods for Pharmacoeconomics & Outcomes Research

**Boisdale (Loch Suite)**

- **Track:** Economic Methods
- **Level:** Introductory  This course is intended for participants with little (or rusty!) statistical training.
- **Faculty:**
  - James Lewsey, PhD, University of Glasgow, Glasgow, UK; Gerd K. Rosenkranz, PhD, Medical University of Vienna, Vienna, Austria

#### Use of Propensity Scores in Observational Studies of Treatment Effects

**Leven+Morar+Ness (Seminar Suite)**

- **Track:** Observational Data Methods
- **Level:** Intermediate  This course is designed for those with little experience with this methodology but some knowledge of observational databases.
- **Prereq.:** Previous attendance at the ISPOR short course, “Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.
- **Faculty:**
  - John D Seeger, PharmD, DrPH, Optum, Waltham, MA, USA; Jeremy A. Rassen, ScD, Aetion, Inc., New York, NY, USA

#### Collecting Health-State Utility Estimates for Economic Models in Clinical Studies

**Carron (Loch Suite)**

- **Track:** Patient Preference Methods
- **Level:** Intermediate  This course is for those with some experience with quality of life measures in health economic evaluation.
- **Faculty:**
  - Sorrel Wolowacz, PhD, RTI Health Solutions, Manchester, UK; Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK; Andrew Lloyd, DPhil, Acaster Lloyd Consulting Ltd., Oxford, UK; Lynda Doward, MRes, RTI Health Solutions, Manchester, UK

#### Pharmacoeconomic Modeling – Applications

**Dochart (Loch Suite)**

- **Track:** Modeling Methods
- **Level:** Intermediate
- **Prereq.:** Previous attendance at, or familiarity with the topics discussed in the ISPOR short course, “Introduction to Modeling,” is required.
- **Faculty:**
  - Shelby L. Corman, PharmD, MS, BCPS, Pharmerit International, Bethesda, MD, USA; Mark S. Roberts, MD, MPP, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

---

`Indicates hands-on exercises requiring the use of your personal computer.`
NEW! Introduction to Designing Authentic and Impactful Patient-Centered Outcomes Research **Hall 1**

Track: Patient-Reported Outcomes Methods  
Level: Introductory  
Faculty: C. Daniel Mullins, PhD, University of Maryland, School of Pharmacy, Baltimore, MD, USA; Marvin Mack, Center for Mind & Esteem Development, Baltimore, MD, USA; Emil Chiauzzi, PhD, PatientsLikeMe, Cambridge, MA, USA

15:00-15:15 **COFFEE BREAK**

17:30-18:30 **EDUCATIONAL SYMPOSIUM (Open to all attendees) Lomond Auditorium (Loch Suite)**  
The Evolving Approach to Drug Value Assessment in Global Markets  
Moderator: David Rees, MBA, Health Strategies Group, Yardley, PA, USA  
Speaker: Sanjay Shah, MBA, Visionary Ventures, LLC., Morganville, NJ, USA; Michael Schlander, MD, PhD, MBA, InnoVal-HC, Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany; Andreas Wildi, MD, Mlaw, Walder Wyss Ltd., Zurich, Switzerland; Jennifer Cain, MBA, MPH, Roche, Basel, Switzerland; Aris Angelis, MSc, London School of Economics and Political Science, London, UK  
*(Sponsored by Health Strategies Group)*
### SUNDAY, 5 NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-18:00</td>
<td><strong>REGISTRATION HELP DESK HOURS</strong> <em>Hall 5</em></td>
</tr>
<tr>
<td>8:00-18:00</td>
<td><strong>EXHIBITOR SET UP</strong> <em>Hall 4</em></td>
</tr>
<tr>
<td>12:00-18:00</td>
<td><strong>SPEAKER READY ROOM HOURS</strong> <em>Fyne (Loch Suite)</em></td>
</tr>
<tr>
<td>8:00-17:00</td>
<td><strong>SHORT COURSE FULL DAY</strong> <em>(Separate Registration Required)</em></td>
</tr>
</tbody>
</table>
| **Bayesian Analysis – Overview and Applications** *Dochart (Loch Suite)* | Track: **Modeling Methods**  
Level: **Intermediate** This course is designed for those with a limited understanding of Bayesian statistical concepts or for those who want a refresher and more practical experience.  
Faculty: Christopher S. Hollenbeak, PhD, Penn State College of Medicine, Hershey, PA, USA; Keith R Abrams, PhD, University of Leicester, Leicester, UK |
| 8:00-12:00 | **SHORT COURSE MORNING SESSION** *(Separate Registration Required)*                                                                            |
Level: **Introductory** This course is designed for those having very minimal experience in understanding differences in perspectives and evidence needs for various access decision makers in the US Health Care system.  
Faculty: Priti Jhingran, PhD, Allergan, Jersey City, NJ, USA; Helen Sherman, PharmD, RPh, Solid Benefit Guidance, Portland, OR, USA |
| **Using DICE Simulation for Health Economic Analyses** *Carron (Loch Suite)* | Track: **Modeling Methods**  
Level: **Introductory** This course is designed for those with some familiarity with modeling.  
Faculty: J. Jaime Caro, MDCM, FRCP, FACP, Evidera, Waltham, MA, USA and McGill University, Montreal, QC, Canada; Jorgen Moller, MSc, Mech Eng, Evidera, Hammersmith, UK |
| **Use of Instrumental Variables in Observational Studies of Treatment Effects** *Gala (Armadillo)* | Track: **Observational Data Methods**  
Level: **Intermediate** This course is suitable for those with some knowledge of econometrics.  
Prereq.: Previous attendance at the ISPOR short course, “Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.  
Faculty: Benjamin M. Craig, PhD, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA; Bradley C. Martin, PharmD, PhD, RPh, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA; Antoine C. El Khoury, PhD, MS, Janssen GCC, Dubai, United Arab Emirates |
| **Transferability and Relevance of Cost-Effectiveness Data Between Countries** *Alsh (Loch Suite)* | Track: **Economic Methods**  
Level: **Advanced** This course is for those with advanced understanding of economic evaluations of health care programs and experience in the critical assessment of cost-effectiveness studies.  
Faculty: Manuela A. Joore, PhD, Care and Public Health Research Institute (CAPHRI) and Maastricht University, Maastricht, The Netherlands; Silvia Evers, PhD, LLM, Maastricht University, Maastricht, The Netherlands |
| **NEW! Mapping to Estimate Utility Values from Non-Preference Based Outcome Measures** *Boisdale (Loch Suite)* | Track: **Patient Preference Methods**  
Level: **Intermediate**  
Faculty: Allan Waistoo, MA, MSc, PhD, University of Sheffield, Sheffield, UK; Mónica Hernández, MSc, PhD, University of Sheffield, Sheffield, UK; Andrea Manca, MSc, PhD, University of York, Heslington, York, UK |

*Indicates hands-on exercises requiring the use of your personal computer.*
Budget Impact Analysis I: A 6-Step Approach  
*Loch Suite*  
**Track:** Economic Methods  
**Level:** Intermediate  
This course is designed for those with some experience with pharmacoeconomic analysis.  
**Faculty:**  
Stephanie R. Earnshaw, PhD, MS, RTI Health Solutions, Research Triangle Park, NC, USA; C. Daniel Mullins, PhD, University of Maryland, School of Pharmacy, Baltimore, MD, USA; Thor-Henrik Brodtkorb, PhD, RTI Health Solutions, Ljungskile, Sweden

Risk-Sharing / Performance-Based Arrangements for Drugs and Other Medical Products  
**Forth (Armadillo)**  
**Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information  
**Level:** Intermediate  
This course is designed for those with some experience with pharmacoeconomic analysis.  
**Prereq.:** Helpful for those taking this course to have completed the ISPOR short course “Elements of Pharmaceutical/Biotech Pricing” or to be familiar with both the key determinants of pharmaceutical pricing and the main international health systems.  
**Faculty:**  
Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA; Adrian Towse, MA, MPhil, Office of Health Economics, London, UK; Josh J. Carlson, MPH, PhD, University of Washington, Seattle, WA, USA

Understanding Survival Modeling with Application to Health Technology Assessment  
**Hall 1**  
**Track:** Modeling Methods  
**Level:** Intermediate  
**Faculty:**  
Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK; Christopher Parker, MSc, Celgene Ltd., Uxbridge, UK; Andrew Davies, MSc, University of Glasgow, Glasgow, UK; Gemma Kay, MSc, ICON Health Economics & Epidemiology, Abingdon, UK

10:00-10:15  
**COFFEE BREAK**  
Coffee Break Sponsored by PHMR

12:00-13:00  
**LUNCH** (Attendees on their own)

13:00-17:00  
**SHORT COURSE AFTERNOON SESSION** (Separate Registration Required)  
Budget Impact Analysis II: Applications & Design Issues  
**Loch Suite**  
**Track:** Economic Methods  
**Level:** Intermediate  
This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to these analyses in Excel.  
**Prereq.:** Participation in the ISPOR short course “Introduction to Budget Impact Analysis: A 6-Step Approach,” or equivalent knowledge, is recommended. Knowledge of Excel is highly recommended.  
**Faculty:**  
Stephanie R. Earnshaw, PhD, MS, RTI Health Solutions, Research Triangle Park, NC, USA; Anita J. Brogan, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; Thor-Henrik Brodtkorb, PhD, RTI Health Solutions, Ljungskile, Sweden

Advanced Methods for Addressing Selection Bias in Real-World Effectiveness and Cost-Effectiveness Studies  
**Loch Suite**  
**Track:** Observational Data Methods  
**Level:** Intermediate  
**Faculty:**  
Richard Grievie, PhD, London School of Hygiene and Tropical Medicine, London, UK; Noemi Kreif, PhD, London School of Hygiene and Tropical Medicine, London, UK

Introduction to the Economic Analysis of Diagnostics  
**Armadillo**  
**Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information  
**Level:** Intermediate  
**Faculty:**  
John E. Schneider, PhD, Avalon Health Economics, Morristown, NJ, USA; Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

Network Meta-Analysis in Relative Effectiveness Research  
**Loch Suite**  
**Track:** Outcomes Research Methods  
**Level:** Intermediate  
This course requires at least a basic knowledge of meta-analysis and statistics.  
**Faculty:**  
Jeroen P. Jansen, PhD, MSc, Chief Scientist, Precision XTract, Oakland, CA, USA; Steve Kanters, MSc, Precision XTract, Vancouver, BC, Canada

Indicates hands-on exercises requiring the use of your personal computer.
Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements Hall 1

Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Intermediate
Faculty: Zoltán Kaló, PhD, Eötvös Loránd University, Budapest, Hungary; Rok Hren, PhD, MSc IHP (HE), University of Ljubljana, Ljubljana, Slovenia; Katarzyna Kolasa, PhD, GHEOR4MEDICALDEVICES and Medical University of Warsaw, Warsaw, Poland

Adjusting for Time-Dependent Confounding and Treatment Switching Bias in Observational Studies and Clinical Trials: Purpose, Methods, Good Practices and Acceptance in Health Technology Assessment Forth (Armadillo)

Track: Observational Data Methods
Level: Intermediate
Faculty: Uwe Siebert, MD, MPH, MSc, ScD, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Nicholas Latimer, MSc, PhD, University of Sheffield, Sheffield, UK; Felicitas Kühne, MSc, UMIT, Hall i.T., Austria

Reimbursement Systems for Pharmaceuticals in Europe Hall 2

Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Intermediate This course is designed for individuals with intermediate experience within a single health care system wishing to broaden their appreciation of other reimbursement systems.
Faculty: Mondher Toumi, MD, PhD, MSc, Aix-Marseille University, Marseille, France

Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications Alsh (Loch Suite)

Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Introductory The course is designed for those unfamiliar with MCDA, but who have a basic understanding of other evaluation methodologies.
Faculty: Maarten J. IJzerman, PhD, University of Twente, Enschede, The Netherlands; Kevin Marsh, PhD, Evidera Ltd, London, UK; Nancy Devlin, PhD, Office of Health Economics, London, UK

15:00-15:15 COFFEE BREAK

17:30-18:30 EDUCATIONAL SYMPOSIUM (Open to all attendees) Lomond Auditorium (Loch Suite)
Evaluating Survival Benefits in Technology Appraisals of Innovative Oncology Drugs: Challenges and Practical Solutions
Moderator: Jipan Xie, MD, PhD, Analysis Group, Inc., Los Angeles, CA, USA
Speakers: Nicholas Latimer, PhD, ScHARR - University of Sheffield, Sheffield, UK; Zheng-Yi Zhou, PhD, Analysis Group, Inc., London, UK
(Sponsored by Analysis Group)

18:45-19:45 EDUCATIONAL SYMPOSIUM (Open to all attendees) Lomond Auditorium (Loch Suite)
How to Use the BEACON Framework to Help Guide the Drug Development Process and Achieve Patient Access
Moderator: Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence, Manchester, UK
Speaker: William Dunlop, MSc, Mundipharma International Ltd, Cambridge, UK; Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Ron Goeree, MA, McMaster University and Goeree Consulting Ltd, Hamilton, ON, Canada
(Sponsored by Mundipharma International Ltd)
### MONDAY, 6 NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-18:00</td>
<td>REGISTRATION HELP DESK HOURS <em>Hall 5</em></td>
</tr>
<tr>
<td>7:15-8:30</td>
<td>ISPOR NUTRITION ECONOMICS SPECIAL INTEREST GROUP OPEN MEETING <em>Forth (Armadillo)</em></td>
</tr>
<tr>
<td>7:30-8:30</td>
<td>ISPOR PATIENT REPORTED OUTCOMES RESEARCH SPECIAL INTEREST GROUP OPEN MEETING <em>Hall 1</em></td>
</tr>
<tr>
<td>7:30-8:30</td>
<td>EDUCATIONAL SYMPOSIUM <em>Lomond Auditorium (Loch Suite)</em></td>
</tr>
<tr>
<td></td>
<td>Real-World Evidence to Support Regulatory Approvals Based on Tumor Biomarkers in Oncology Research</td>
</tr>
<tr>
<td></td>
<td>Moderator: Bruce Feinberg, DO, Cardinal Health Specialty Solutions, Dublin, OH, USA</td>
</tr>
<tr>
<td></td>
<td>Speakers: Bjorn Bolinder, MBA, AstraZeneca, Gaithersburg, MD, USA; Hui Huang, PhD, MBA, Takeda, Cambridge, MA, USA; Samuel Wagner, PhD, RPh, Bristol-Myers Squibb, Washington Crossing, PA, USA (Sponsored by Cardinal Health)</td>
</tr>
<tr>
<td>8:00-18:00</td>
<td>SPEAKER READY ROOM HOURS <em>Fyne (Loch Suite)</em></td>
</tr>
<tr>
<td>8:30-19:45</td>
<td>EXHIBIT/POSTER HALL HOURS <em>Hall 4</em></td>
</tr>
<tr>
<td>8:45-13:45</td>
<td>RESEARCH POSTERS - SESSION I <em>Hall 4</em></td>
</tr>
<tr>
<td>8:45-10:45</td>
<td>WELCOME &amp; FIRST PLENARY SESSION <em>Clyde Auditorium (Armadillo)</em></td>
</tr>
<tr>
<td></td>
<td>WELCOME FROM ISPOR CEO/EXECUTIVE DIRECT</td>
</tr>
<tr>
<td></td>
<td>Nancy S. Berg, BSc, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA</td>
</tr>
<tr>
<td></td>
<td>PRESIDENTIAL ADDRESS</td>
</tr>
<tr>
<td></td>
<td>Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA</td>
</tr>
<tr>
<td></td>
<td>CONGRESS PROGRAM OVERVIEW FROM PROGRAM COMMITTEE CO-CHAIRS</td>
</tr>
<tr>
<td></td>
<td>Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK</td>
</tr>
<tr>
<td></td>
<td>Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>FIRST PLENARY SESSION: Where is the Value in Value-Based Health Care?</td>
</tr>
<tr>
<td></td>
<td>Moderator: Maarten J. Ijzerman, PhD, University of Twente, Enschede, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Speakers: Peter Naredi, University of Gothenburg and European CanCer Organization (ECCO), Brussels, Belgium; Luke Slawomirski, Organisation for Economic Co-operation and Development (OECD), Paris, France; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and European Society for Medical Oncology (ESMO), Uppsala, Sweden; Jason Arora, MD, MPH, Medtronic, Watford, UK</td>
</tr>
<tr>
<td>10:45-11:15</td>
<td>BREAK, EXHIBITS &amp; RESEARCH POSTERS - SESSION I <em>Hall 4</em></td>
</tr>
<tr>
<td>11:15-12:15</td>
<td>BREAKOUT SESSION</td>
</tr>
<tr>
<td></td>
<td><strong>IP1</strong>: Pragmatic Clinical Trials to Estimate Treatment Effects: Are They Worth the Effort? <em>Hall 3</em></td>
</tr>
<tr>
<td></td>
<td>Moderator: Rita M. Kristy, MS, Astellas Pharma Global Development, Northbrook, IL, USA</td>
</tr>
<tr>
<td></td>
<td>Panelists: Keith R. Abrams, PhD, CStat, University of Leicester, Leicester, UK; Christoph Gerlinger, PD, Bayer AG, Berlin, Germany; Helene Karcher, PhD, Analytica Laser, Loerrach, Germany</td>
</tr>
<tr>
<td></td>
<td><strong>IP2</strong>: How to Improve Consistency of Orphan Drug Pricing and Reimbursement in Europe? Application of the ‘Orph-Val’ Principles in Germany, France, and the United Kingdom <em>Clyde Auditorium (Armadillo)</em></td>
</tr>
<tr>
<td></td>
<td>Moderator: Lieven Annemans, PhD, MSc, Ghent University - Brussels University, Ghent, Belgium</td>
</tr>
<tr>
<td></td>
<td>Panelists: Karina Ehrig, PhD, Federal Joint Committee (G-BA), Berlin, Germany; Francois Meyer, PhD, Haute Autorité de Santé (HAS), Saint-Denis, France; Sheela Upadhyaya, MSc, National Institute for Health and Care Excellence (NICE), London, UK</td>
</tr>
<tr>
<td></td>
<td><strong>W1</strong>: Where Do We Need Good Research Practice Guidance in Health Technology Assessment? <em>Hall 2</em></td>
</tr>
<tr>
<td></td>
<td>Discussion Leaders: Finn Borlum Kristensen, MD, PhD, University of Southern Denmark, Hilleroed, Denmark; Mirjana Huić, MD, PhD, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia; Wim Goetttsch, PhD, The National Healthcare Institute (ZIN), Dieren, The Netherlands; Sophie Werkö, PhD, MSc, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden</td>
</tr>
</tbody>
</table>
P1: Cost-Effectiveness Studies Lomond Auditorium (Loch Suite)

CE1  Cost-Effectiveness of Dabigatran With Real World Effectiveness Evidence

CE2  Cost-Effectiveness Analysis of Midostaurin (Mido) With Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)
11:30-11:45  Tremblay G1, Dolph M2, Patel S3, Brandt P4, Forsythe A1, Purple Squirrel Economics, New York, NY, USA, 2Novartis Pharmaceuticals UK Limited, Camberley, Surrey, UK, 3Novartis Pharmaceuticals, East Hanover, NJ, USA

CE3  First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis
11:45-12:00  From a UK Healthcare Perspective

cE4  The Effectiveness and Cost-Effectiveness of Tobacco Control Mass Media Campaigns in Scotland
12:00-12:15  Haqpanaham BH, Boyd KA1, Mackay DF2, McIntosh E3, Pell J4, Haw S5, University of Glasgow, Glasgow, UK, 2University of Stirling, Stirling, UK

P2: Cancer Studies Forth (Armadillo)

CN1  Use of New Therapies and Hospital Admission Near the End of Life in Castration Resistant Prostate Cancer (CRPC) in the Castration Resistant Prostate Cancer Registry (CAPRI) in The Netherlands
11:15-11:30  Kuppen M1, Westgeest H2, Van den Eertwegh A3, Gerritsen W4, Uyl - de Groot C5, Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands, 3Radboud University Medical Center, Nijmegen, The Netherlands

CN2  The Greta Study: Generating Real-World Evidence About Bevacizumab Treatment of Metastatic Colorectal Cancer by Linking Cancer Registries and Healthcare Databases in Italy
11:30-11:45  Franchi M1, Caputo A2, Barni S3, De Ceglie MC4, Mazzucco W5, Ricci P6, Taglialube G7, Tomino R8, Corraro G9, University of Milano-Bicocca, Milano, Italy, 2Roche S.p.A., Monza, Italy, 3ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, Italy, 4Roche S.p.A., Monza, Italy, 5University of Palermo, Palermo, Italy, 6Health Protection Agency Mantua&Cremona, NHS Italy, Mantova, Italy, 7Fondazione IRCCS National Cancer Institute, Milano, Italy, 8Provincial Health Authority, ASP Ragusa, Ragusa, Italy, 9Università di Milano-Bicocca, Milano, Italy

CN3  Assessing the Consistency in Reporting of Adverse Events Across Data Sources for Multiple Myeloma
11:45-12:00  Treatment

Kish J1, Fernberg B1, Cardinal Health Specialty Solutions, Dallas, TX, USA, 2Cardinal Health, Dublin, OH, USA

CN4  Utilization and Treatment Patterns Among Patients With Advanced Non-Small Cell Lung Cancer Receiving Predictive Molecular Biomarker (BMX) Tests
12:00-12:15  Kothari S1, Arunanachalam A2, Tsao M3, Lee DH4, Kambartel K5, Isobe H6, Huang M7, Escosteguy Barrios CH8, Khattak A9, de Marinis F10, Cao X11, Burke T12, Lopez MA13, de Castro J14, 1Merck & Co, Kenilworth, NJ, USA, 2Merck & Co., Inc., North Wales, PA, USA, 3University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada, 4University of Palermo, Palermo, Italy, 5University of Milano-Bicocca, Milano, Italy, 6Roche S.p.A, Monza, Italy, 7University of Stirling, Stirling, UK, 8Provincial Health Authority, ASP Ragusa, Ragusa, Italy, 9Università di Milano-Bicocca, Milano, Italy

12:15-14:15  LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION I  Hall 4
Lunch Sponsored by Health Economics and Outcomes Research Ltd.

12:30-13:30  ISPOR DIGEST OF DATABASES SPECIAL INTEREST GROUP OPEN MEETING  Hall 1

12:45-13:45  ISPOR STUDENT RESEARCH SHOWCASE Lomond Auditorium (Loch Suite)
Moderators: Zeba Khan, MS, RPh, PhD, Celgene Corporation, Summit, NJ, USA; Laura Pizzi, MPH, RPh, PharmD, Rutgers University, Piscataway, NJ, USA
Speakers: Natalie J. Williams, Msc, NIHR Nottingham Hearing Biomedical Research Unit, Nottingham, UK; Junjie Ma, Msc, University of Utah, Salt Lake City, UT, USA; Omer Ben-Aharon, MBA, MHA, Bar-Ilan University, Ramat Gan, Israel; Fanni Soikkeli, University of Eastern Finland, Joensuu, Kuopio and Savonlinna, Finland
12:45-13:45  EDUCATIONAL SYMPOSIUM Clyde Auditorium (Armadillo)

**HTA V2.0: The Relevance of Real-World Evidence in Value Frameworks and Its Relation with Regulatory and Health Technology Assessment Convergence**

Moderator: Jacco Keja, PhD, IQVIA, London, UK

Speakers: Maureen Rutten-van Mólkken, PhD, MSc, Erasmus School of Health Policy & Management (ESHPM), Rotterdam, The Netherlands; Dana Vigier, MD, BMS, Ruei-Malmaison, France; Elizabeth Powers, MBA, IQVIA, New York, NY, USA

(Sponsored by IQVIA)

12:45-13:45  POSTER AUTHOR DISCUSSION HOUR - SESSION I Hall 4

14:15-15:15  BREAKOUT SESSION

**IP3: Unmet (Medical) Need: Should Stakeholders Align on a Definition? Hall 2**

Moderator: Claudine Sapede, PharmD, MSc, F. Hoffmann-La Roche Ltd, Basel, Switzerland


**IP4: Value Added Medicines: Time to Adjust the Health Technology Assessment Decision Frameworks? Clyde Auditorium (Armadillo)**

Moderator: Michael Drummond, MCom, DPhil, University of York, Harlesden, York, UK

Panelists: Pascal Auquier, MD, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France; Luigi Burgio, MSc, Tева Italia S.r.l., Assago (MI), Italy; Mondher Toumi, MD, PhD, MSc, Aix-Marseille University, Marseille, France

**W3: Making Patient Reported Outcomes Measurement Meaningful: Best Practices for Presenting Patient Reported Outcomes Data to Patients, Clinicians, and Decision Makers Hall 3**

Discussion Leaders: Jakob B. Bjørner, MD, PhD, Optum Patient Insights, Johnston, RI, USA; Michael Brundage, MSc, FRCPC, MD, Queen's University, Kingston, ON, Canada; Claire Snyder, MHS, PhD, Johns Hopkins School of Medicine, Baltimore, MD, USA; Martha Bayliss, MSc, Optum Patient Insights, Johnston, RI, USA

**W4: Bridging the Gap: Best Practices in Navigating Diverging Perceptions of Regulators and Payers on Non-Traditional Clinical Trial Endpoints Forth (Armadillo)**

Discussion Leaders: Mark Chalmers, PhD, CBPartners, London, UK; Caroline Solon, MSc, CBPartners, San Francisco, CA, USA; Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Lung-Cheng, PhD, Takeda, Zurich, Switzerland

**P3: Studies on Health Technology Assessment Agencies Lomond Auditorium (Loch Suite)**

**HT1** Playing in the Same Pond - The Impact of Brexit on Clinical Trials and Access


**HT2** Health Technology Assessment Decisions in Immuno-Oncology Therapies: Results, Rationales, and Trends

14:30-14:45  Campbell CM, Nguyen VB, Clark RS, Meyer KL, Xcenda, LLC, Palm Harbor, FL, USA

**HT3** Analysis of Factors Influencing the Level of Actual Benefit in Health Technology Assessment

14:45-15:00  Bouschon M1, Li J1, Barthelémy C1, 1Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, 2Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France, 3Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France

**HT4** Using Real-World Data (RWD) in Health Technology Assessment (HTA) Practice: A Comparative Study of

15:00-15:15  5 HTA Agencies

Makady A1, van Veelen A1, Jonsson P1, Moseley O1, D’Andon A1, de Boer A1, Hillegel JL1, Klungel O2, Goettsch W1, 1The National Healthcare Institute (ZIN), Dieren, The Netherlands, 2Utrecht University, Utrecht, The Netherlands, 3National Institute for Health and Care Excellence (NICE), Manchester, UK, 4Scottish Medicines Consortium, 50 West Nile Street, UK, 5French National Authority for Health, Saint Denis La Plaine, France, 6University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 7Utrecht University, Utrecht, The Netherlands

**P4: Research on Methods Hall 1**

**RM1** Network Meta-Analysis of Hazard Ratios Vs. Fractional Polynomials Approach in a Cost-Effectiveness

14:15-14:30  Analysis Considering Advanced Gastric Cancer

Cramner HL, Harvey RC, Tolley Health Economics Ltd., Buxton, UK

**RM2** Multivariate Network Meta-Analysis of Survival Function Parameters

14:30-14:45  Cope S1, Chan K1, Jansen JP1, 1Precision Health Economics, Vancouver, BC, Canada, 2Precision Health Economics, Los Angeles, CA, USA

**RM3** Methods for Extracting Treatment Patterns for Renal Cell Carcinoma (RCC) From Social Media (SM)

14:45-15:00  Forums Using Natural Language Processing (NLP) and Machine Learning (ML)

Merinopoulou E1, Ramagopalan S1, Malcolm B1, Cox A1, 1Evidera, London, UK, 2Bristol-Myers Squibb, Uxbridge, UK

**RM4** Non-Proportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis

15:00-15:15  Gsteiger S1, Windisch R1, Bryden P1, Wiksten A2, 1F. Hoffmann-La Roche Ltd, Basel, Switzerland, 2StatFinn & EPID Research, Espoo, Finland
15:00-16:00  CAREER ADVICE ACROSS THE GLOBE - THE ART OF GETTING PUBLISHED  
Alsh (Loch Suite)  
Speakers: Lyn Beamesderfer, International Society for Pharmacoeconomics and Outcomes Research, Lawrensville, NJ, USA; C. Daniel Mullins, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA; Diego Rosselli, MD, MEd, MHP, Pontificia Universidad Javeriana, Bogotá, Colombia; Dan Greenberg, PhD, Ben-Gurion University of the Negev, Beer-Sheva, Israel

15:15-15:45  BREAK & EXHIBITS  
Hall 4  
Coffee Break Sponsored by Ingress Health

15:45-16:45  BREAKOUT SESSION

IP5: European HTA 2020: What is the Road Map to Effective Permanent Cooperation? (Invited Issue Panel)  
Hall 2  
Moderator: Tim Wilsdon, Charles Rivers Associates, London, UK  
Panelists: Wim Goetttsch, EUneHTA JA3 Directorate, The National Healthcare Institute (ZIN), Diemen, The Netherlands; Adrian Griffin, Johnson & Johnson, Buckinghamshire, UK; Nicola Bedlington, European Patients Forum (EPF), Brussels, Belgium; Flora Giorgio, Directorate General for Health and Food Safety (DG SANTE), European Commission, Brussels, Belgium

IP6: Are Existing Health Technology Assessment Requirements Inadequate for Establishing Value for Potentially Transformative Gene Therapies?  
Hall 3  
Moderator: Kellie Meyer, PharmD, MPH, Xcenda, Palm Harbor, FL, USA  
Panelists: Ron Akehurst, PhD, BresMed Health Solutions, Sheffield, UK; Clark Paramore, MSPH, bluebird bio, Cambridge, MA, USA; Adrian Towse, MA, MPH, Office of Health Economics, London, UK

W5: Sustainable Funding and Fair Pricing for Orphan Drugs: What Are the Solutions?  
Lomond Auditorium (Loch Suite)  
Discussion Leaders: Martina Garau, MSc, Office of Health Economics, London, UK; Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK; Saskia Knies, PhD, National Health Care Institute (ZIN), Diemen, The Netherlands; Ulf Staginnus, MBA, Shire plc, Zug, Switzerland

W6: Generating Real-World Evidence for Real-World Decisions: Application of Advanced Methods  
Clyde Auditorium  
Discussion Leaders: Mark Sculpher, PhD, University of York, York, UK; Richard Grieve, PhD, London School of Hygiene and Tropical Medicine, London, UK; Anirban Basu, PhD, University of Washington, Seattle, WA, USA; Stephen Oneill, MEconSc PhD, National University of Ireland, Galway, Galway, Ireland

P5: Medication Adherence Studies  
Hall 1

AD1: Exploring Factors Explaining Treatment Acceptance in Patients Suffering From a Chronic Disease  
15:45-16:00  
Wiederkehr S1, de Bock E2, Chekrout M3, Arnould B4, Mapi, Patient Centered Sciences, Lyon, France; Mapi, Patient Centered Outcomes, Lyon, France; Mapi, Patient Centered Outcomes, Lyon, France

AD2: The Impact of Pharmacist-Led Medication Therapy Management on Medication Adherence in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Study  
16:00-16:15  
Erku DA, Belachew SA, Tegegn HG, Ayele AA, University of Gondar, Gondar, Ethiopia

AD3: Factors Associated With an Adherence With Antiepileptic Drugs in Children Treated in Pediatric Practices in Germany  
16:15-16:30  
Kostev K1, Dombrowski S2, Jacob L3, QuintilesIMS, Frankfurt am Main, Germany; University of Paris 5, Paris, France

AD4: Predictive Analysis for Identifying Patient Characteristics Associated With Primary Medication Nonadherence for Lipid Lowering Therapies  
16:30-16:45  
Hill JW1, Rane PB2, Hines DM3, Patel J4, Harrison DJ5, Wade RL6, QuintilesIMS, Plymouth Meeting, PA, USA; Amgen Inc., Thousand Oaks, CA, USA

P6: Mental Health Studies  
Armadillo

MH1: Discrete Event Simulation Modelling of Long Term Cost-Effectiveness of Internet-Based Blended Cognitive Behavioural Therapy for Major Depressive Disorder: Extrapolation of the E-Compared Randomised Controlled Trial  
15:45-16:00  
O’Connell MM1, Kolovos S2, Bomsans JE3, Forbes JP4, E-COMPARED Consortium5, University of Limerick, Limerick, Ireland; Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; E-COMPARED Consortium, Europe, Ireland

MH2: Adherence Patterns Among Patients Using Oral Atypical Antipsychotics and Other Medications  
16:00-16:15  
Shafrin J1, Lakdawalla DN2, MacEvian JP3, Silverstein AR4, Hatch A5, Forma F6, Precision Health Economics, Los Angeles, CA, USA; University of Southern California, Los Angeles, CA, USA; ODH, Inc., Princeton, NJ, USA; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA

MH3: Model Structure of Patient-Level Models for Schizophrenia: A Systematic Literature Review  
16:15-16:30  
Zhou J1, Millier A2, Dorey J3, Aballéa S4, Toumi M5, Aix-Marseille University, Marseille, France; Creativ-Ceutical, Paris, France

MH4: Family Caregiving in Dementia and Its Impact on Quality of Life and Economic Burden in Japan – Web-Based Survey  
16:30-16:45  
Igarashi A1, Fukuda A2, Teng L3, Ma F4, Dorey J5, Onishi Y6, University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan; Creativ-Ceutical, Beijing, China; Creativ-Ceutical, Paris, France; Creativ-Ceutical K.K., Tokyo, Japan

SCHEDULE OF EVENTS

MONDAY

ISPOR 20th Annual European Congress
The Evolution of Value in Health Care

Coffee Break Sponsored by Ingress Health

Break & Exhibits

Breakout Session

European HTA 2020: What is the Road Map to Effective Permanent Cooperation?

Sustainable Funding and Fair Pricing for Orphan Drugs: What Are the Solutions?

Generating Real-World Evidence for Real-World Decisions: Application of Advanced Methods

Medication Adherence Studies

Mental Health Studies
ISPOR 20th Annual European Congress
The Evolution of Value in Health Care

SCHEDULE OF EVENTS
MONDAY

15:45-19:30 RESEARCH POSTERS - SESSION II Hall 4

17:00-18:00 BREAKOUT SESSION

IP7: ‘Mind the Gap!’: How Should We Manage the Difference Between Regulatory and Reimbursement Evidence Requirements for Medical Devices? Clyde Auditorium (Armadillo)
Moderator: Bjorn Schwander, AHEAD GmbH (Agency for Health Economic Assessment and Dissemination), Lorrach, Germany
Panelists: Richard Charter, MSc, Becton Dickinson, Basel, Switzerland; Karen Facey, PhD, University of Edinburgh, Edinburgh, UK; Nneka C. Onwudive, PhD, PharmD, MBA, FDA, Silver Spring, MD, USA

IP8: Forecasting Pharmaceutical Expenditure in Europe: Is It Sustainable? Lomond Auditorium (Loch Suite)
Moderator: Jorge Mestre-Ferrandiz, PhD, Independent Economics Consultant, Madrid, Spain
Panelists: Tim Davis, MSc, IQVI, Basel, Switzerland; Claudio Jommi, PhD, SDA Bocconi School of Management, Milano, Italy; Panos Kanavos, PhD, London School of Economics and Political Science, London, UK

W7: Value of Information (VOI) Analysis for Research Decisions: Emerging Good Practice Recommendations From the ISPOR VOI Task Force Hall 2
Discussion Leaders: Elisabeth Fenwick, PhD, MSc, ICON plc, Abingdon, UK; Saskia Kniest, PhD, National Health Care Institute (ZIN), Dieren, The Netherlands; Hendrik Koffijberg, PhD, University of Twente, Enschede, The Netherlands; Claire Rothery, PhD, University of York, York, UK

W8: Modeling Separate Lines of Treatment Versus Treatment Sequences in Cancer Hall 3
Discussion Leaders: Agnes Benedict, MSc, Evidera, Budapest, Hungary; Matthew Stevenson, PhD, University of Sheffield, Sheffield, UK; Sonja Sörensen, MPH, Evidera, Bethesda, MD, USA

P7: Conceptual Papers Hall 1
17:00-17:15 Macaulay R, Hettle R, PAREXEL International, London, UK

CP2 Using Outcome Data to Inform Healthcare Professional – Patient Discussion: A Database of Treatment Effects
17:15-17:30 Gilbert J, National Guidelines Centre, London, UK

CP3 The Future of Precision Medicine: What Does It Mean for NICE?
17:30-17:45 Rejon-Parrilla JC, Lovett RE, Chalkidou A, Love-Koh J, Wood H, Ennis K, Peel A, Taylor M, National Institute for Health and Care Excellence (NICE), Manchester, UK; National Institute for Health and Care Excellence (NICE), London, UK; King’s Technology Evaluation Centre (KITEC), King’s College London, London, UK; York Health Economics Consortium, University of York, York, UK

CP4 Challenges in Optimising Real World Evidence for Alzheimer’s Disease
17:45-18:00 Reed C, de Reydet de Vulpillieres P, Gallacher J, Eli Lilly and Company Ltd, Windlesham, UK; Novartis Pharma AG, Basel, Switzerland; Oxford University, Oxford, UK

P8: Cardiovascular Studies Forth (Armadillo)
CV1 Interim Results of a Multi-Country Survey to Evaluate Productivity Loss and Indirect Costs After Cardiovascular Events in Europe
17:00-17:15 Gerlier L, Sidelnikov E, Kutikova L, Lamotte M, Amarenco P, Kotseva K, Annemans L, QuintilesMS, Zaventem, Belgium; Amgen (Europe) GmbH, Zug, Switzerland; Bichat Hospital-Claude Bernard, Paris, France; National Heart & Lung Institute, Imperial College London, London, UK; Ghent University - Brussels University, Ghent, Belgium

CV2 A Framework for the Cost-Effectiveness Analysis of Novel Biomarker Testing in Cardiovascular Disease
17:15-17:30 Kohli-Lynch CN, Boyd K, Briggs A, Delles C, University of Glasgow, Glasgow, UK

CV3 CYP2C19 Guided Antiplatelet Therapy: A Cost-Effectiveness Analysis of 30-Day and One-Year Outcomes Following Percutaneous Coronary Intervention
17:30-17:45 Dong OM, Borse MS, Polasek MJ, Farley JF, Stouffer GA, Lee CR, University of North Carolina, Chapel Hill, NC; QuintilesMS, Durham, NC, USA

CV4 Cost Model for a New Acoustic Diagnostic Aid to Rule Out Coronary Artery Disease
17:45-18:00 Winther S, Böttcher MP, Wahler S, Bolin K, Aarhus University Hospital, Aarhus N, Denmark; Hjerteforskningsklinikken, Herning, Denmark; St. Bernward GmbH, Hamburg, Germany; University of Gothenburg, Gothenburg, Sweden

18:00-19:45 EXHIBITORS' OPEN HOUSE RECEPTION & RESEARCH POSTERS - SESSION II Hall 4
ISPOR wishes to thank the Lord Provost & Glasgow City Council for their ongoing assistance, and for their generosity in providing a special welcome drink at Monday evening Exhibitor Reception.
Reception Sponsored by Complete HEOR Solutions (CHEORS)

www.ispor.org | 19
**ISPOR 20th Annual European Congress**

**The Evolution of Value in Health Care**

**SCHEDULE OF EVENTS**

**MONDAY**

**18:15-19:15**  
**BREAKOUT SESSION**

**F1: Better, Cheaper, Faster: A Report on the Science of Optimization From the ISPOR Optimization Task Force**  
*Hall 3*

Moderator: Alec Morton, PhD, University of Strathclyde, Glasgow, Scotland, UK

Speakers: Nasuh Buyukkaramikli, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands; Praveen Thokala, MAsc, PhD, The University of Sheffield, Sheffield, UK; Jon Tosh, MSc, PhD, DRG Abacus, Manchester, UK

Presented by the ISPOR Optimization Task Force

**F2: Methods and Preliminary Results of the ISPOR Oncology Health Economic Modeling Special Interest Group**  
*Hall 2*

Moderator: Noemi Muszbek, MSc, Evidera, London, UK

Speakers: Agnes Benedict, MSc, Evidera, Budapest, Hungary; Sergio Iannazzo, MBA, SIHS Health Economics Consulting, Torino, Italy; Nermeen Nabil Ashoush, PhD, The British University in Egypt, Cairo, Egypt; Hena Qureshi, BSc, BA, University of Calgary, Calgary, AB, Canada

Presented by the Oncology Health Economic Modeling – Post-Progression Working Group of the ISPOR Oncology Special Interest Group

**F3: Rare Disease Research, Health Technology Assessment and Evidence for Reimbursement**  
*Clyde Auditorium (Armadillo)*

Moderator: Sandra Nestler-Parr, PhD, MPhil, MSc, Rare Access Ltd., London, UK

Speakers: Ken Redekop, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands; Christopher M. Blanchette, PhD, MBA, Precision Health Economics, Charlotte, NC, USA; Sheela Upadhyaha, BSc, National Institute for Health and Care Excellence, London, UK; Janis Clayton, BSc, PTC Therapeutics Ltd., Dublin, Ireland

Presented by the ISPOR Rare Disease Special Interest Group

**F4: Could Multi-Stakeholder Partnership Improve Patient Access to Better Health Care in Latin America?**  
*Hall 1*

Moderator: Ramiro E. Gilardino, MD, MSc, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Lawrenceville, NJ, USA

Speakers: Diego F Guarin, MD, MPH, MA, Merck-Serono, Billerica, MA, USA; Diego Rosselli, MD, Pontificia Universidad Javeriana, Bogota, Colombia; Federico Augustovski, MD, MSc, PhD, University of Buenos Aires, Buenos Aires, Argentina; Nicola Bedlington, The Patient Access Partnership PACT, Brussels, Belgium

Presented by the Latin America Consortium

**F5: Rare Diseases MCDA Criteria Implementation Results in European Countries**  
*Lomond Auditorium (Loch Suite)*

Moderator: Olha Zaliska, PhD, DSci (Pharm), Danylo Halitsky Lviv National Medical University, Lviv, Ukraine

Speakers: John Yfantopoulos, PhD, University of Athens, Athens, Greece; Francesco Saverio Mennini, MSc, University Tor Vergata Roma, Rome, Italy; Tarik Catic, PhD(s), Health Economics and Pharmacoeconomics, Sarajevo, Bosnia; Rok Hren, PhD, MSc IHP(HE), Institute of Mathematics, Physics and Mechanics, Ljubljana, Slovenia

Presented by the ISPOR CEE Consortium and ISPOR Italy-Rome Chapter

**F6: The Establishment of Negotiation Committee, Therapeutic Guidelines and Health Technology Assessment Efforts in CEE Countries**  
*Forth (Armadillo)*

Moderator: Magda Hatzikou, PhD, Novartis Hellas SA, Athens, Greece

Speakers: Zoltan Kalo, PhD, Syreon Research Institute, Budapest, Hungary; Dragana Atanasijevic, MD, MSc, Institute of Public Health of Serbia, Belgrade, Serbia; Joanna Lis, PhD, Sanofi, Warsaw, Poland; Mary Geitona, MD, University of Peloponnese, Korinthos, Greece

Presented by the ISPOR CEE Consortium

**18:15-19:15**  
**ISPOR STATED PREFERENCE METHODS SPECIAL INTEREST GROUP OPEN MEETING**  
*Boisdale (Loch Suite)*

**18:30-19:30**  
**POSTER AUTHOR DISCUSSION HOUR - SESSION II**  
*Hall 4*

**19:45-21:00**  
**ISPOR STUDENT AND NEW PROFESSIONALS MIXER**  
*Mezzanine*

**19:45-21:00**  
**ISPOR CENTRAL & EASTERN EUROPE (CEE) CONSORTIUM RECEPTION**  
*Gala Foyer (Armadillo)*
## TUESDAY, 7 NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-18:00</td>
<td><strong>REGISTRATION HELP HOURS Hall 5</strong></td>
</tr>
<tr>
<td>7:30-8:30</td>
<td><strong>EDUCATIONAL SYMPOSIUM Lomond Auditorium (Loch Suite)</strong></td>
</tr>
</tbody>
</table>
|            | *Changing the Health Technology Assessment Paradigm for Combination Therapies*  
| Moderator: | Mark Ratcliffe, PhD, PHMR Ltd, London, UK                           |
| Speakers:  | Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Claudio Jommi, MSc, CERGAS Bocconi University, Milan, Italy; Hanim Edoo, MSc, Medipal Qualite Omega, Paris, France; Jaime Caro, MDCM, MRCGP, FACP, Evidera, Bethesda, MD, USA  
| (Sponsored by Takeda Pharmaceuticals International AG) |
| 7:45-8:45  | **ISPOR BIOSIMILAR SPECIAL INTEREST GROUP OPEN MEETING Boisdale (Loch Suite)** |
| 8:00-18:00 | **SPEAKER READY ROOM HOURS Fyne (Loch Suite)**                        |
| 8:30-19:15 | **EXHIBIT/POSTER HALL HOURS Hall 4**                                  |
| 8:45-9:45  | **BREAKOUT SESSION**                                                  |
| IP9:       | *Should Rare Oncology Treatments Be Considered True Orphans? Lomond Auditorium (Loch Suite)*  
| Moderator: | Mark Sculpher, PhD, University of York, York, UK                     |
| Panelists: | Karl Claxton, PhD, University of York, York, UK; Ross Maclean, MD, Precision Health Economics, Los Angeles, CA, USA; Jens Grueger, PhD, F Hoffmann-La Roche, Division Pharma, Basel, Switzerland  |
| IP10:      | *Does Valuation of Innovation in Appraisal of New Technologies Provide Appropriate Incentives for Manufacturers and Access for Patients? Hall 2*  
| Moderator: | Karl Claxton, PhD, University of York, York, UK; Ross Maclean, MD, Precision Health Economics, Los Angeles, CA, USA; Jens Grueger, PhD, F Hoffmann-La Roche, Division Pharma, Basel, Switzerland  |
| Panelists: | Karl Claxton, PhD, University of York, York, UK; Ross Maclean, MD, Precision Health Economics, Los Angeles, CA, USA; Jens Grueger, PhD, F Hoffmann-La Roche, Division Pharma, Basel, Switzerland  |
| Discussion Leaders: | Rosemary Lovett, PhD, National Institute for Health and Care Excellence (NICE), London, UK; Allan Wailoo, MA, MSc, PhD, University of Sheffield, Sheffield, UK; Nancy Devlin, PhD, Office of Health Economics, London, UK  |
| W10:       | *EQ-SD: Is NICE Ready for the Next Level? Hall 3*                       |
| Panelists: | Karl Claxton, PhD, University of York, York, UK; Ross Maclean, MD, Precision Health Economics, Los Angeles, CA, USA; Jens Grueger, PhD, F Hoffmann-La Roche, Division Pharma, Basel, Switzerland  |
| MD1:       | *Do We Know Enough Yet? A Cumulative Cost-Effectiveness Analysis of Mechanical Thrombectomy*  
| 8:45-9:00  | Teljeur C, Ryan M, Glynn R, Harrington P, Health Information and Quality Authority, Dublin, Ireland; *Health Information and Quality Authority (HIQA)*, Dublin, Ireland; *Health Service Executive* Dublin, Ireland; *Health Information and Quality Authority*, Dublin 7, Ireland  |
| MD2:       | *South West IECRs – The Experience of NICE’s Diagnostics Assessment Programme*  
| 9:00-9:15  | Nixon F, Walker T, Maloney J, Albrow R, National Institute for Health and Care Excellence, Manchester, UK  |
| MD3:       | *Cost-Effectiveness of Diagnosis: From Tests to Long-Term Outcomes and Costs*  
| 9:15-9:30  | Faria R, Soares M, Spackman E, Ahmed H, Brown L, Kaplan RS, Emberton M, Sculpher M, University of York, Hospital, York, UK; *University of York*, York, UK; *University of California*, Los Angeles, CA, USA; *Imperial College Healthcare NHS Trust*, London, UK; *MRC Clinical Trials Unit at UCL*, London, UK; *University College Hospitals NHS Foundation Trust*, London, UK  |
| MD4:       | *Evaluating Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison Techniques: Impact on Health-Related Quality of Life of Focused Ultrasound Thalamotomy and Other Interventions for the Treatment of Medication-Refractory Essential Tremor*  
| 9:30-9:45  | Langford BE, Ridley CI, Beale RC, Marsh W, Casey SC, Richard L, Costello Medical Consulting Ltd, Cambridge, UK; *Costello Medical Consulting Ltd*, London, UK; *InSightec Ltd*, Tirat Carmel, Israel  |
| P10:       | *Methods in Patient Preference Studies Gala (Armadillo)*  
| PP1:       | *Mimicking Real Life Decision-Making in Health: Allowing Respondents Time-To-Think in a Discrete Choice Experiment*  
| 8:45-9:00  | Veldwijk J, Viberg Johansson J, Donkers B, de Bekker-Grob E, Erasmus University Rotterdam, Rotterdam, The Netherlands; *Uppsala University*, Uppsala, Sweden  |
SCHEDULE OF EVENTS

ISPOR 20th Annual European Congress
The Evolution of Value in Health Care

TUESDAY

9:00-9:15
Gunsoy NB1, Cockle SM2, Doyle S1, Asukai Y1, 1GSK, Uxbridge, UK, 2GSK, Brentford, Middlesex, UK

PP3  The Comparative Performance of the CHU-9D and ADQOL Amongst Children Aged 5 Years or More With Eczema: Evidence From the Clothes Randomised Controlled Trial
9:15-9:30
Sach TH1, McManus E1, Thomas K2, Montgomery A2, Harrison E1, Williams H2, on behalf of the CLOTHES trial team1, 1University of East Anglia, Norwich, UK, 2University of Nottingham, Nottingham, UK

PP4  Does Using Factor Analysis to Select Covariates in Mapping Algorithms Improve Predictive Accuracy? A Case of Mapping the Core 23-Item Women's Health Questionnaire Onto the EQ-5D-5L and SF-6D
9:30-9:45
Kaambwa B1, de Lacey S1, Smith C1, Ratcliffe J1, 1Flinders University, Adelaide, Australia, 2University of South Australia, Adelaide, Australia

8:45-13:30  RESEARCH POSTERS - SESSION III Hall 4

9:45-10:15  BREAK, EXHIBITS & RESEARCH POSTERS - SESSION III Hall 4
Coffee Break Sponsored by Covance

10:15-12:00  WELCOME & SECOND PLENARY SESSION Clyde Auditorium (Armadillo)
WELCOME FROM ISPOR PRESIDENT
Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA

WELCOME FROM ISPOR CHIEF SCIENCE OFFICER
Richard J. Willke, PhD, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA

2017 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
AWARDEE: Claire Rothery, PhD, University of York, Heslington, York, UK

2017 VALUE IN HEALTH REGIONAL ISSUES (CEEWAA) EXCELLENT ARTICLE AWARD
AWARDEE: Aleš Tichopád, PhD, Kantar Health s.r.o., Prague, Czech Republic

SECOND PLENARY SESSION: Appraising the Appraisers: What is the Future of Health Technology Assessment in Europe?
Moderator: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK
Speakers: Susan Guthrie, PhD, MSci, Rand Europe, Cambridge, UK; Nicola Allen, PhD, Precision for Value, London, UK; Zoe Garrett, MPhil, MRes, National Institute for Health and Care Excellence (NICE) and EUnetHTA, Manchester, UK

12:00-14:00  LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION III Hall 4
Lunch Sponsored by BaseCase Management GmbH

12:30-13:30  ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING Lomond Auditorium (Loch Suite)

12:30-13:30  ISPOR PATIENT CENTERED SPECIAL INTEREST GROUP OPEN MEETING Lomond Auditorium (Loch Suite)

12:30-13:30  EDUCATIONAL SYMPOSIUM Clyde Auditorium (Armadillo)
Practical Implications of Value-Based Pricing and Emerging Value Frameworks in Health Technology Assessment
Moderator: Jay Jackson, PharmD, MPH, Xcenda, Palm Harbor, FL, USA
Speakers: Andrew Briggs, DPhil, MSc, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Ansgar Hebborn, PhD, F.Hoffmann-La-Roche AG, Basel, Switzerland; Ken O’Day, PhD, MPA, Xcenda, Palm Harbor, FL, USA
(Sponsored by Xcenda)

12:30-13:30  POSTER AUTHOR DISCUSSION HOUR - SESSION III Hall 4

22 | #ISPORGlasgow
12:30-14:00  ISPOR WOMEN IN HEOR/SCIENCE OPEN MEETING  
**Boisdale (Loch Suite)**

ISPOR is exploring the foundation of a “Women in HEOR/Science” initiative to help support the growth, development, and contribution of women in health economics and outcomes research (HEOR) and to serve as a catalyst for women’s leadership in the field. The objective of this session is to share the vision for the initiative and to gain feedback from members to help guide its development.

**Speakers:** 2017-2018 ISPOR President, Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA; Olivia Wu, PhD, University of Glasgow, Glasgow, UK

14:00-15:00  BREAKOUT SESSION

**IP11:** Determining Value in Health Technology Assessment Consistent with Societal Aims: Pursue New Options?  
**Hall 2**

**Moderator:** J. Jaime Caro, MDCM, FRCPC, FACP, McGill University, Montreal, QC, Canada

**Panelists:** Alistair McGuire, MLitt, PhD, London School of Economics and Political Science, London, UK; John Brazier, PhD, MSc, University of Sheffield, Sheffield, UK; Michael Schlander, MD, PhD, MBA, Institute for Innovation & Valuation in Health Care (InnoValHC), Wiesbaden, Germany

**IP12:** What Should Patient-Centered Care Mean in the Welfare States of Europe? The United Kingdom and Germany Cannot Both Be Right  
**Hall 3**

**Moderator:** F. Reed Johnson, PhD, Duke Clinical Research Institute, Durham, NC, USA

**Panelists:** Axel C. Mühlbacher, PhD, MBA, Hochschule Neubrandenburg, Neubrandenburg, Germany; Nancy Devlin, PhD, Office of Health Economics, London, UK

**W11:** Determining the Value of Long Term Outcomes Associated With Immuno-Oncology Therapies - Challenges and Approaches for OS Extrapolations  
**Armadillo**

**Discussion Leaders:** Yiduo Zhang, PhD, AstraZeneca, Gaithersburg, MD, USA; Pralay Mukhopadhyay, PhD, AstraZeneca, Gaithersburg, MD, USA; Andrew Briggs, DPhil, MSc, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Nicholas Latimer, MSc, PhD, University of Sheffield, Sheffield, UK

**W12:** Getting to the Heart of the Matter: Real-World Evidence as an Indispensable Source for the Ongoing Assessment of Cardiovascular Treatments  
**Armadillo**

**Discussion Leaders:** Kathleen E. Hughes, MBA, Avalere Health LLC, Washington, DC, USA; Colin Berry, FRCP, PhD, University of Glasgow, Glasgow, UK; Pall Jonsson, PhD, National Institute for Health and Care Excellence (NICE), Manchester, UK; Martin Zagari, MD, Amgen Inc, Thousand Oaks, CA, USA

P11: Cost Studies  
**Hall 1**

**CS1** Observed Versus Estimated Acquisition Costs Associated With Medicines Recommended by the All Wales Medicines Strategy Group  
**14:00-14:15**

Deslandes PN, Haines K, Routledge PA, All Wales Therapeutics and Toxicology Centre, Llandough, UK

**CS2** Costs of Chemotherapy-induced Adverse Events in Head and Neck Cancer in France  
**14:15-14:30**

Lafuma A1, Cotte F1, Le Tourneau C1, Emery C1, Gaudin A1, Torreton E1, Gourmelon P1, Ouared C1, Bonastre J6, Cemka-Eval, Bour La Reine, France; 2 Bristol-Myers Squibb, Rueil-Malmaison, France; 3 Institut Curie, Paris, France; 4 Gustave Roussy, Villejuif, France

**CS3** Costs of Illness Progression for Different Multiple Sclerosis Phenotypes: A Population-Based Study in Sweden  
**14:30-14:45**


**CS4** Real Life Cost of Treatment and Follow-up Glioblastoma Multiforme (GBM) Patients Treated at the Antwerp University Hospital (UZA), Belgium  
**14:45-15:00**

Van den Eede N1, De Paepe A1, Specenier P2, Strens D3, University of Antwerp, Antwerpen, Belgium; 2 Antwerp University Hospital, Edegem, Belgium; 3 Realidad bvba, Grimbergen, Belgium

P12: Modeling  
**Lomond Auditorium (Loch Suite)**

**MO1** Calibration Approach Impact on Health and Cost-Effectiveness Outcomes in a Decision Analytic Framework  
**14:00-14:15**

Morina D, Díaz M, Catalan Institute of Oncology, L’Hospital de Llobregat, Spain

**MO2** How Ireland’s Colorectal Screening Programme Could Save More Lives, Save Money and Stay Within Existing Colonoscopy Capacity Limits: Evidence From the MISCAN Microsimulation Model  
**14:15-14:30**

McFerran E1, O’Mahony JP1, Queen’s University Belfast, Belfast, UK; 2 Trinity College Dublin, Dublin, Ireland

**MO3** Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology  
**14:30-14:45**

Majer IM1, Castaigne J2, Palmer S3, DeCosta L4, Campioni M1, 1 Amgen (Europe) GmbH, Zug, Switzerland; 2 Amgen Oncology, Cambridge, UK; 3 University of York, Heslington, York, UK; 4 Amgen Ltd., Uxbridge, UK

**MO4** Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness and Cost-Effectiveness Analyses  
**14:45-15:00**

Keene Y1, Dawoud D1, Dias S1, 1 University of Bristol, Bristol, UK; 2 National Guideline Centre, Royal College of Physicians, London, UK
15:00-15:30  BREAK & EXHIBITS  Hall 4

15:30-16:30  BREAKOUT SESSION


Moderator: Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA

Panelists: Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; Maarten Ijzerman, PhD, MSc, University of Twente, Enschede, The Netherlands; Nancy Livne, PhD, Office of Health Economics, London, UK


Moderator: Finn Borlum Kristensen, MD, PhD, University of Southern Denmark, Hilleroed, Denmark

Panelists: Katharine Barnard, PhD CPsychol AFBPsS, Bournemouth University, Poole, UK; Simon O’Neill, REG.N., Diabetes UK, London, UK; Francois Meyer, PhD, Haute Autorité de Santé (HAS), Saint-Denis, France


Discussion Leaders: Elisabeth Fenwick, PhD, MSc, ICON plc, Abingdon, UK; Hendrik KoffiJberg, PhD, University of Twente, Enschede, The Netherlands; Beate Jahn, PhD, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Koen Degeling, MSc, University of Twente, Enschede, The Netherlands

**W14: Impact of Patient Involvement in Health Technology Assessments: A Case Study Hall 2**

Discussion Leaders: Matthew May, BS, EPF, Brussels, Belgium; Joan Jordan, Multiple sclerosis Society of Ireland, Dublin, Ireland; Michael Barry, MB, FRCP, PhD, National Centre for Pharmacoeconomics (NCPE), Dublin, Ireland; Orlaith Brennan, MBA, Irish Pharmaceutical Industry Association, Dublin, Ireland

**P13: Methodological Studies in Cancer Hall 1**

**CN5** Progression-Free Survival As a Surrogate Endpoint for Overall Survival in Patients With Relapsed or Refractory Multiple Myeloma 15:30-15:45

Dimitopoulos M1, Sonneveld P1, Nahi H1, Kumar S1, Hashim M1, Kulakova M1, Duran M1, Heeg B1, Lam A1, Dearden L, National and Kapodistrian University of Athens, Athens, Greece; Erasmus MC, Rotterdam, The Netherlands; Karolinska Institute, Stockholm, Sweden; Mayo Clinic, Rochester, MN, USA; Ingress Health, Rotterdam, The Netherlands; Janssen Global Services, LLC, Raritan, NJ, USA

**CN6** Can Bayesian Methodology Predict Long-Term Effectiveness Rather Than Efficacy? An Application With Overall Survival in Two Oncology Indications 15:45-16:00

Soikkeli P1, Hashim M1, Mueller S1, Groth A1, Wilke T1, Heeg B1, Ingress Health, Rotterdam, The Netherlands; Ingress-Health HWM GmbH, Wismar, Germany; INGRESS-Health HWM GmbH, Wismar, Germany

**CN7** Estimating Long-Term Survival in the Face of Immature Data: A Case Study of Nivolumab in Second Line Renal Cell Carcinoma 16:00-16:15

Klin S1, Torkiseng EB1, Tyas D1, Sowdani A1, Malcolm B1, Mudd A1, Johannesen KM1, Pharment International, Rotterdam, The Netherlands; Bristol-Myers Squibb, Lysaker, Norway; Bristol-Myers Squibb, Uxbridge, UK; Bristol-Myers Squibb AB, Stockholm, Sweden

**CN8** Length of Trial Period and Fit of Standard Survival Extrapolation Distributions for Ipilimumab in Melanoma 16:15-16:30

Ouwens MJ1, Dalevi D, Astrazeneca, Molndal, Sweden

**P14: Systemic Disorders/Conditions Studies Forth (Armadillo)**

**SY1** Psoriasis Drugs in Europe - Market Access Decisions in Comparison Based on the Prism Access Database 15:30-15:45

Vollmer L1, de Paz B1, Droeschel D1, Walzer S1, MAR SYSTEMS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany; PRIORITYIS Market Access, Paris, France

**SY2** WITHDRAWN

**SY3** How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents As Therapy Areas Become Crowded With Drugs With Similar Mechanisms of Action? 15:45-16:00

Paglia R1, Del Carlo A, Schwartz J, Carter EA, Consulting at McCann Health, New York, NY, USA

**SY4** Do EU5 Countries With Favoured Healthcare Expenditure and Reimbursement Indicators Have Better Patient-Reported Access to Treatments for Rare Diseases? 16:00-16:15

Allen G1, Hall A1, Hanman K1, Le Fevre R1, Griffiths A1, Costello Medical Consulting Ltd, Cambridge, UK; Costello Medical Consulting Ltd, London, UK

15:30-19:15  RESEARCH POSTERS - SESSION IV  Hall 4
ISPOR 20th Annual European Congress
The Evolution of Value in Health Care

SCHEDULE OF EVENTS
TUESDAY

16:45-17:45  BREAKOUT SESSION
IP15: A Modest Proposal: Can We Ease the Burden of Myriad Measures with a Minimum Data Set That Actually Matters to Patients?  Hall 1
Moderator: Roman Casciano, MS, ANALYTICA LASER, New York, NY, USA
Panelists: Sheela Upadhyaya, MSc, NICE - National Institute for Health and Care Excellence, London, UK; Charles D. Petrie, PhD, Pfizer Inc., Groton, CT, USA; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and Uppsala University, Uppsala, Sweden

IP16: Managed Entry Schemes for Medical Devices: Great Opportunity or Major Challenge?  Hall 3
Moderator: Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK
Panelists: Aleksandra Torbica, PhD, Bocconi University, Milano, Italy; Richard Charter, MSc, Becton Dickinson, Allschwil, Switzerland; Denis Gizzi, BSc, Sheffield Hallam University, Oldham, UK

W15: Time for a Change? Alternative Approaches to Modelling in Cancer Value Assessments  Clyde Auditorium (Armadillo)
Discussion Leaders: Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence (NICE), London, UK; Robert Hettle, MMath, Parexel International, London, UK; Beth Woods, MSc, University of York, Heslington, York, UK; Marta Soares, MSc, University of York, Heslington, York, UK

W16: Understanding the Value and Feasibility of Engaging Patients in the Design of Clinical Trials and Clinical Outcome Assessment Measurement Strategies: Insights from Experiences in Oncology and Gout  Lomond Auditorium (Loch Suite)
Discussion Leaders: Bryan Bennett, PhD, Adelphi Values Ltd, Bollington, Cheshire, UK; Sophi Tatlock, MA, Adelphi Values Ltd, Bollington, Cheshire, UK; Stephanie Manson, PhD, Novartis, East Hanover, NJ, USA; Katja Rudell, PhD, Queen Mary University of London, London, UK

P15: Health Technology Assessment Studies  Hall 2
HT5 “Appraising The Appraisers”: Do National Health Technology Assessment Agencies (NICE, GBA/IQWIG) Follow Their Official Evaluation Criteria?
16:45-17:00  Schaefer R1, Schwarz O2, Schlander M3, 1German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany; 2University of Heilbronn, Wiesbaden, Germany; 3University of Heidelberg, Heidelberg, Germany

HT6 Assessment of Medicines for Very Rare Conditions: Review of a New Approach Within the Scottish Medicines Consortium
17:00-17:15  Jones J, Brown A, Lee A, MacDonald A, Healthcare Improvement Scotland, Glasgow, UK

HT7 What Do the Single Technology Appraisals of the Past Tell Us About Fast-Tracking the Most Cost-Effective New Technologies in the Future?
17:15-17:30  Boland A1, Houten R1, Carroll C2, Kaltenthaler E2, Dickson R1, 1University of Liverpool, Liverpool, UK; 2University of Sheffield, Sheffield, UK

HT8 The Use of Published Real-World Evidence in HTA: An Analysis of the Evidence Base of Company Submissions in 2016 NICE Appraisals
17:30-17:45  Van Lier H, de Boeck M, Edwards V, Hanekamp E, Hartog TE, Richmond G, van den Broek R, Excerpta Medica, Amsterdam, The Netherlands

P16: Infectious Disease Studies  Forth (Armadillo)
IN1 Estimating the Public Economic Impact of Different Hepatitis C Healthcare Policies in the Netherlands
16:45-17:00  Connolly M1, Kotsoopoulos N2, 1University of Groningen, Groningen, The Netherlands; 2Global Market Access Solutions, Saint-Prex, Switzerland

IN2 Cost-Effectiveness and Modeling Approaches of Direct-Acting Antiviral Agents in Chronic Hepatitis C Infection: A Systematic Literature Review
17:00-17:15  Szilberhorn L1, Agh T1, Fasseeh AN2, Kaló Z2, 1Eötvös Loránd University (ELTE), Budapest, Hungary; 2Syreon Research Institute, Budapest, Hungary

IN3 Differences in Vaccine Pricing Between High-Income and Low-Income Markets
17:15-17:30  Fadeyi I, McLean T, Tavella F, Heron L, Adelphi Values Ltd, Bollington, UK

IN4 Cost-Effectiveness of Additional Vaccination of Boys Against HPV in Germany
17:30-17:45  Damm O1, Horn J1, Ultsch B2, Scholz S3, Nikolajczyk R4, Wiese-Posselt M1, Harder T1, Wichmann O1, Greiner W1, 1School of Public Health, Bielefeld University, Bielefeld, Germany; 2Helmholtz Centre for Infection Research, Brunswick, Germany; 3Immunisation Unit, Robert Koch Institute, Berlin, Germany

17:45-19:15  EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTERS - SESSION IV  Hall 4
Reception Sponsored by Pharmerit International

www.ispor.org | 25
18:00-19:00  BREAKOUT SESSION

F7: Health State Utility Identification and Use in Cost-Effectiveness in Decision Modelling  Clyde Auditorium (Armadillo)
Moderator: John Brazier, PhD, MSc, University of Sheffield, Sheffield, UK
Speakers: Helene Chevrou-Severac, PhD, Celgene International, Boudry, Switzerland; Roberta Ara, MSc, The University of Sheffield, Sheffield, UK; Andrew Lloyd, DPhil, Acaster Lloyd Consulting Ltd., Oxford, UK
Presented by ISPOR Health State Utility Good Practices Task Force

F8: Innovation and Market Access in Asia-Pacific: What Evidence and Processes Are Appropriate for Reimbursement? China, Japan, South Korea, Taiwan and Australia Compared  Hall 3
Moderator: Mendel Grobler, B.Pharm, MBA, Amgen Inc., North Ryde, NSW, Australia
Speakers: Shanlian Hu, MS, MD, Shanghai Health Development Research Center, Shanghai, China; Bruce Crawford, MPH, MA, InVentiv Health Japan G.K., Tokyo, Japan; Sukyeong Kim, PhD, RPh, MPH, Coordinating Center for National Health Clinical Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South); Chee-Jen Chang, PhD, MS, Taiwan Society for Pharmacoeconomics and Outcome Research, Clinical Informatics and Medical Statistics Research Center, and Professor, Chang Gung University, Tao Yuan, Taiwan
Presented by ISPOR Asia Consortium Industry Committee

F9: Late Stage Oncology MCDA Criteria Implementation Results in European Countries  Hall 1
Moderator: Vladimir Zah, PhD, ZRx Outcomes Research Inc., Belgrade, Serbia
Speakers: Oresta Piniazhko, PhD, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine; Niki Popper, University of Technology Vienna, Vienna, Austria; Aleksandra Zawodnik, MSc Pharm, Medical University of Warsaw, Warsaw, Poland; Bertalan Nemeth, MSc, Syreon Research Institute, Budapest, Hungary
Presented by the ISPOR CEE Consortium and ISPOR Austria Chapter

F10: The Burden of COPD in Central & Eastern Europe  Forth (Armadillo)
Moderator: Maria Kamusheva, PhD, Medical University of Sofia, Sofia, Bulgaria
Speakers: Josip Culig, MD, PhD, Andrija Stampar Institute of Public Health, Zagreb, Croatia; Konstantin Tachkov, PhD(c), Medical University of Sofia, Sofia, Bulgaria; Tamas Agh, MD, MSC, PhD, Syreon Research Institute, Hungary, Hungary; Mary Geitona, MD, University of Peloponnese, Korinthos, Greece
Presented by the ISPOR CEE Consortium

Moderator: Carme Pinyol, MD, PhD, MSc, Pierre Fabre, Barcelona, Spain
Speakers: César Hernández, PhD, Spanish Agency of Medicines and Health Products, Barcelona, Spain; Jorge Mestre-Ferrandiz, PhD, OHE Collaborator, Madrid, Spain
Presented by ISPOR Spain Chapter

F12: Implementing Adaptive Pathways in Europe: A Central and Eastern Europe (CEE) Focus  Hall 2
Speakers: André Broekmans, MD, PhD, Lygature and ADAPT SMART, Utrecht, The Netherlands; Zoltán Kaló, PhD, Eötvös Loránd University (ELTE) and Syreon Research Institute, Budapest, Hungary; Tomas Tesar, PharmD, PhD, MBA, MPH, Msc, Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovak Republic; Dominik Tomel, PharmD, MPH, PhD, MSc, European Patients Forum and Association for Patients’ Right Protection in Slovakia, Bratislava, Slovakia

18:15-19:15  POSTER AUTHOR DISCUSSION HOUR - SESSION IV  Hall 4

19:30-23:30  ISPOR SOCIAL EVENT  (Separate Registration Required)  Merchant Square
Join us for whisky tasting, dinner, and traditional dancing and music.

The event takes place at Merchant Square, once part of the old Glasgow Fruit Market, in the heart of Glasgow.

Guests will enjoy Scottish appetizers, whisky tasting, and have a choice of dinner options at the 5 restaurants within Merchant Square. A demonstration of Ceilidh dancing will be given and all will have the opportunity to participate in this easy-to-learn traditional dancing.

Separate registration required. The price is £90 and includes transportation from the SEC to Merchant Square and back to the SEC, buffet dinner, 2 drinks, and entertainment. Registration subject to availability, see the ISPOR Registration desk for details.
- If you have pre-registered for the Social Event, your ticket will print out with your name badge. You will need this ticket for entry to the bus/event.
- Buses will depart from the SEC between 19:30 and 20:00 for the 15-minute journey to Merchant Square.
- Return buses will start at 21:00, last bus at 23:15.
WEDNESDAY, 8 NOVEMBER

7:30-8:30  EDUCATIONAL SYMPOSIUM Lomond Auditorium (Loch Suite)
Universal Value, The Way Forward?
Speakers: Michael Blackney, PhD, Covance Market Access, London, UK; Ruth Zeidman, PhD, Covance Market Access, London, UK; Emanuela Castelnuovo, MSc, Covance Market Access, London, UK; Michael F. Drummond, MCom, DPhil, University of York, Heslington, York, UK; Don Redding, BA, National Voices, London, UK
(Sponsored by Covance)

8:00-16:00  REGISTRATION HELP DESK HOURS Hall 5
8:00-15:30  SPEAKER READY ROOM HOURS Fyne (Loch Suite)
8:30-14:15  EXHIBIT/POSTER HALL HOURS Hall 4
8:45-14:00  RESEARCH POSTERS - SESSION V Hall 4
8:45-9:45  BREAKOUT SESSION
IP17: Deriving Utility Measures from Disease-Specific Quality of Life Instruments: Does Mapping to Generic Utility Instruments Adequately Capture the Patient Perspective in Economic Evaluation? Hall 3
Moderator: Samuel Aballéa, PhD, Creativ-Ceutical, Paris, France
Panelists: Linda Abetz-Webb, MA, Patient-Centred Outcomes Assessments, Bollington, UK; Keith Tolley, Tolley Health Economics Ltd., Buxton, UK; Clément François, PhD, Lundbeck, Deerfield, IL, USA
IP18: How Will Health Care Systems Handle Future Oncology Combination Product Launches? Hall 2
Moderator: Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and Uppsala University (Department EBC), Uppsala, Sweden
Panelists: Martina Weiss-Radtke, MBA, Helsana Versicherungen AG, Zurich, Switzerland; Jens Grueger, PhD, F. Hoffmann-LaRoche, Division Pharma, Basel, Switzerland; Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence, Manchester, UK
IP19: Can the Patient Voice Be Better Incorporated Into the NICE Process? Lomond Auditorium (Loch Suite)
Moderator: Eric Low, NA, East Lothian, UK
Panelists: Jennifer Lee, MBA, Janssen UK, High Wycombe, UK; Heidi Livingstone, BA, NICE, London, UK; Richard Jackson, PGCE, NPOH, Patient Expert, Cheshire, UK
W17: Comparing, Contrasting, and Validating Health Economic Decision Models: Experiences From the Latest Mt. Hood Challenge in Diabetes and Lessons for Other Disease Areas Hall 1
Discussion Leaders: Alan Brennan, PhD, University of Sheffield, Sheffield, UK; Mark Lamotte, MD, IQVIA, Zaventem, Belgium; Talitha Feenstra, PhD, RIVM /UMCG, Bilthoven, The Netherlands; Michael Willis, PhD, The Swedish Institute for Health Economics, Lund, Sweden
W18: From One to Many: When Groups – Not Czars – Make Decisions Forth (Armadillo)
Discussion Leaders: Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; Guruprasad Madhavan, PhD, National Academies of Science, Engineering, and Medicine, Washington, DC, USA
9:45-10:00  BREAK, EXHIBITS & RESEARCH POSTERS - SESSION V Hall 4
10:00-11:00  BREAKOUT SESSION
IP20: Should ICER Be NICE (or Not)? How ICER’s New Cost-Effectiveness Framework Compares with NICE’s Guidelines Hall 3
Moderator: Matthew Sussman, MA, Boston Health Economics, Waltham, MA, USA
Panelists: Dan Ollendorf, PhD, Institute for Clinical and Economic Review, Boston, MA, USA; Pall Jonsson, PhD, National Institute for Health and Care Excellence (NICE), Manchester, UK
Moderator: David Schwicker, MA, ORPHA Strategy Consulting, Basel, Switzerland
**SCHEDULE OF EVENTS**
**ISPOR 20th Annual European Congress**
**The Evolution of Value in Health Care**

**WEDNESDAY**

**IP22: How Can We Assess the Value of New Antibiotics? Lomond Auditorium (Loch Suite)**
Moderator: Chris Henshall, PhD, Office of Health Economics, London, UK
Panelists: Alec Morton, PhD, University of Strathclyde, Glasgow, Scotland, UK; Douglas Lundin, PhD, TLV, Stockholm, Sweden; Adrian Towse, MA, MPH, Office of Health Economics, London, UK

**W19: Generating Evidence to Support Off-Label Higher Value Cancer Treatment Regimens Hall 1**
Discussion Leaders: Mark Sculpher, PhD, University of York, York, UK; Mark J. Ratain, MD, FASCO, The University of Chicago, Chicago, IL, USA; Peter Clark, MA, MD, FRCP, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK; Virginia Acha, PhD, MSD Ltd., Hertfordshire, UK

Discussion Leaders: Howard Thom, MSc, PhD, University of Bristol, Bristol, UK; Joy Leahy, BSc, Trinity College Dublin, Dublin, Ireland; Jeroen P. Jansen, PhD, Precision Health Economics, Vancouver, BC, Canada

**11:15-12:45 WELCOME & THIRD PLENARY SESSION Clyde Auditorium (Armadillo)**
**WELCOME FROM ISPOR PRESIDENT, PRESENTATION OF ISPOR DISTINGUISHED SERVICE AWARDS, AND ANNOUNCEMENT OF ISPOR 21ST ANNUAL EUROPEAN CONGRESS**
Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA

AWARDEES: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK
Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands

**THIRD PLENARY SESSION: Evolution of Value: Perspectives From Both Sides of the Atlantic**
Moderator: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA
Speakers: Mandy Ryan, PhD, MSc, University of Aberdeen, Aberdeen, UK; Charles E. Phelps, PhD, University of Rochester, Highland, CA, USA; Jérôme Wittwer, PhD, Bordeaux University, Bordeaux, France

**12:45-14:15 LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION V Hall 4**

**13:00-14:00 EDUCATIONAL SYMPOSIUM Lomond Auditorium (Loch Suite)**
**Does Accelerated Approval Deliver Accelerated Access? Experiences, Challenges, and Priorities**
Moderator: Victoria Tzouma, MSc, London School of Economics and Political Science, London, UK
Speakers: Panos Kanavos, PhD, London School of Economics and Political Science, London, UK; Chris Hoyle, PhD, AstraZeneca, Cambridge, UK
(Sponsored by AstraZeneca)

**13:00-14:00 POSTER AUTHOR DISCUSSION HOUR - SESSION V Hall 4**

**14:15-15:15 BREAKOUT SESSION**

**IP23: How Do You Incorporate the Patient Perspective into Health Technology Assessments? Defining Best Practices for Rigorous Scientific Evidence and Impactful Submissions and Reviews Hall 3**
Moderator: Judith Leah Rubinstein, MIA, Context Matters Inc., New York, NY, USA
Panelists: Paola Kruger, MA, Accademia dei Pazienti/EUPATI Italia, Rome, Italy; Ken Bond, MA, CADTH, Ottawa, ON, Canada; Laure Delbecque, PhD, Pharmerit International, Rotterdam, The Netherlands

**IP24: Trusting the Results of Model-Based Economic Analyses: Is There a Pragmatic Validation Solution? Hall 2**
Moderator: J. Jaime Caro, MDCM, FRCP, FACP, McGill University, Montreal, QC, Canada
Panelists: Matt Stevenson, PhD, University of Sheffield, Sheffield, UK; Jorgen Moller, MSc, Mech Eng, Evidera, Hammersmith, UK; Salah Ghabri, PhD, Haute Autorité de Santé, Saint-Denis La Plaine, France

**IP25: Innovative Clinical Trial Designs: Welcomed by Regulators But What About the Payers? Forth (Armadillo)**
Moderator: Richard Macaulay, PhD, PAREXEL International, London, UK
Panelists: Leanne Larson, MHA, PAREXEL International, Waltham, MA, USA; Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Detlev Parow, MD, MBA, D A K - Gesundheit, Hamburg, Germany

**W21: Comparing Treatments by Combining Data from Various Randomized and Observational Studies: Introduction to Concept, Methods, and Application Hall 1**
Discussion Leaders: Viktor Chirikov, PhD, Pharmerit International, Bethesda, MD, USA; Susanne Schmitz, PhD, Luxembourg Institute of Health, Strassen, Luxembourg; Farhan Mughal, MRPharms, MSc, Celgene Ltd, Uxbridge, UK

**W22: Negotiating Price and Data in an Era of Conditional Approval: “Stick” or “Twist”? Lomond Auditorium (Loch Suite)**
Discussion Leaders: Daniel Gladwell, MSc, BresMed Health Solutions LTD, Sheffield, UK; Warren Cowell, MSc, Janssen Inc., High Wycombe, UK; Mark Strong, PhD, University of Sheffield, Sheffield, UK, Ash Bullemer, BSc, BresMed Health Solutions, Sheffield, UK
ISPOR 20th Annual European Congress  
The Evolution of Value in Health Care

**SCHEDULE OF EVENTS**

**WEDNESDAY**

15:15-15:30  **BREAK**  

15:30-16:30  **BREAKOUT SESSION**

**IP26: mHealth Among Clinicians and Patients in Cancer Care: How to Address the Digital Divide? Forth (Armadillo)**
Moderator: Rosanna Tarricone, PhD, Bocconi University, Milan, Italy  
Panelists: Maria Cucciniello, PhD, Bocconi University, Milan, Italy; Roma Maguire, PhD, MSc, University of Surrey, Glasgow, UK; Nicola Scalzo, MSc, European Commission, Brussels, Belgium

**IP27: Valuing Children’s HRQoL for Health Technology Assessment: What Are the Issues and Challenges? Hall 2**
Moderator: Nancy Devlin, PhD, Office of Health Economics, London, UK  
Panelists: Oliver Rivero-Arias, PhD, MSc, University of Oxford, Oxford, UK; Donna Rowen, PhD, University of Sheffield, Sheffield, UK; Deborah Morrison, MSc, NICE, Manchester, UK

**IP28: Patient Preferences in European Drug Regulation – Are We Ready? Hall 1**
Moderator: Douwe Postmus, PhD, University Medical Center Groningen, Groningen, The Netherlands  
Panelists: Francesco Pignatti, MD, European Medicines Agency, London, UK; Pierre Demolis, MD, PhD, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Saint-Denis, France; Tommi Tervonen, PhD, Eidera, London, UK

Discussion Leaders: Hoa Van Le, MD, PhD, PAREXEL International, Durham, NC, USA; Aaron WC Kamauu, MD, MS, MPH, Anolinx LLC, Salt Lake City, UT, USA; Schiffon L Wong, MPH, EMD Serono, Inc., Billericia, MA, USA

**W24: Population-Adjusted Treatment Comparisons in Health Technology Assessment: An Overview of Approaches and Perspectives Hall 3**
Discussion Leaders: David M. Philippo, MSc, University of Bristol, Bristol, UK; Ahmed Elsaad, MSc, National Institute for Health and Clinical Excellence, Manchester, UK; Mark Belger, BSc, Eli Lilly and Company, Surrey, UK; Nicky J. Welton, PhD, MSc, University of Bristol, Bristol, UK

< advertisement >

Mark your Calendars!

**UPCOMING ISPOR EVENTS**

**23RD ANNUAL INTERNATIONAL MEETING**
May 19-23, 2018  
Baltimore, MD, USA  
Abstract Submission Deadline: January 17, 2018  
Early Registration Deadline: April 10, 2018

**8TH ASIA-PACIFIC CONFERENCE**
8-11 September 2018  
Tokyo, Japan  
Abstract Submission Opens: 1 November 2017  
Abstract Submission Deadline: 14 March 2018  
Early Registration Deadline: 17 July 2018

**21ST ANNUAL EUROPEAN CONGRESS**
10-14 November 2018  
Barcelona, Spain  
Abstract Submission Opens: 1 March 2018  
Abstract Submission Deadline: 13 June 2018  
Early Registration Deadline: 25 September 2018
Independent analytical expertise to help innovators discover, validate, and articulate the value of medical technologies

Tuesday, November 7
8:45 am – 1:30 pm
Changes in Acute Medication Cost Observed in Cluster Headache Patients Treated with Sphenopalatine Ganglion (SPG) Stimulation: A UK NHS-Specific Analysis Based on Data from the Pathway R1 Registry
(Research Posters III, abstract PMD34)

Clinical and Economic Benefit of Upper Airway Stimulation for Obstructive Sleep Apnea in the German Setting
(Research Posters III, abstract PMD51)

wing-tech.com • consulting@wing-tech.com • +1-650-943-3000
Menlo Park, CA • Irvine, CA • Potomac, MD • Karlsruhe, Germany

Visit us at the 2017 ISPOR European Congress, booth 113
## Invitational Group Meetings

The following is a list of the by invitation only ISPOR group meetings during ISPOR Glasgow. ISPOR members worldwide are actively participating in ISPOR working groups to advance global health outcomes research and the use of this research in health care decisions. These ISPOR groups provide an opportunity for members to contribute to translating outcomes research to health care decisions.

*Please note: invitees will receive an email reminder and notification of any changes to this ISPOR group meeting schedule*

### SUNDAY, 5 NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-15:00</td>
<td>ISPOR HTA Roundtable - Europe</td>
<td>Gallery Bistro (upstairs off the Mezzanine)</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>ISPOR Publications Management Advisory Board and Journal Editors-in-Chief Joint Business Meeting</td>
<td>Katrine (Seminar Suite)</td>
</tr>
<tr>
<td>12:00-12:45</td>
<td>ISPOR HTA Roundtable - Europe Luncheon</td>
<td>Gallery Bistro (upstairs off the Mezzanine)</td>
</tr>
<tr>
<td>14:30-17:30</td>
<td>ISPOR Health Science Policy Council</td>
<td>Morar-Ness (Seminar Suite)</td>
</tr>
<tr>
<td>15:30-17:30</td>
<td>ISPOR HTA Roundtable - Middle East and Africa</td>
<td>Gallery Bistro (upstairs off the Mezzanine)</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>ISPOR Health Science Policy Council Breakout</td>
<td>Katrine (Seminar Suite)</td>
</tr>
<tr>
<td>17:45-18:45</td>
<td>ISPOR Africa Network Executive Committee</td>
<td>Leven (Seminar Suite)</td>
</tr>
</tbody>
</table>

### MONDAY, 6 NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15-14:15</td>
<td>Lunch for delegates served in the Exhibit Poster Hall</td>
<td></td>
</tr>
<tr>
<td>7:15-8:15</td>
<td>ISPOR Value &amp; Outcomes Spotlight Editorial Board</td>
<td>Carron (Loch Suite)</td>
</tr>
<tr>
<td>7:30-8:30</td>
<td>ISPOR Statistical Methods in Health Economics and Outcomes Research Special Interest Group</td>
<td>Morar-Ness (Seminar Suite)</td>
</tr>
<tr>
<td>7:30-8:30</td>
<td>ISPOR Asia Consortium Business Meeting</td>
<td>Alsh (Loch Suite)</td>
</tr>
<tr>
<td>12:00-13:45</td>
<td>ISPOR Health State Utility Estimates in CE Models Task Force</td>
<td>Katrine (Seminar Suite)</td>
</tr>
<tr>
<td>12:00-14:00</td>
<td>ISPOR Institutional Council Lunch</td>
<td>Leven (Seminar Suite)</td>
</tr>
<tr>
<td>12:15-14:00</td>
<td>ISPOR Value in Health Editorial Board and Editorial Advisory Board</td>
<td>Morar-Ness (Seminar Suite)</td>
</tr>
<tr>
<td>12:30-17:00</td>
<td>ISPOR Patient Representatives Roundtable</td>
<td>Gallery Bistro (upstairs off the Mezzanine)</td>
</tr>
<tr>
<td>13:45-15:15</td>
<td>ISPOR Expert Elicitation Task Force</td>
<td>Katrine (Seminar Suite)</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>ISPOR Arabic Network Executive Committee</td>
<td>Carron (Loch Suite)</td>
</tr>
<tr>
<td>14:15-15:15</td>
<td>ISPOR Poland Chapter</td>
<td>Morar-Ness (Seminar Suite)</td>
</tr>
<tr>
<td>15:00-16:00</td>
<td>ISPOR Global Engagement Council</td>
<td>Leven (Seminar Suite)</td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>ISPOR Chapters of the Eurasian Economic Union Countries Joint Meeting</td>
<td>Dochart (Loch Suite)</td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>ISPOR Greece Chapter</td>
<td>Boisdale (Loch Suite)</td>
</tr>
<tr>
<td>15:15-16:45</td>
<td>ISPOR Proposed Stated Preference Methods in Decision Making Good Practices Task Force</td>
<td>Katrine (Seminar Suite)</td>
</tr>
<tr>
<td>16:30-17:30</td>
<td>ISPOR Hungary Chapter</td>
<td>Boisdale (Loch Suite)</td>
</tr>
<tr>
<td>16:30-17:30</td>
<td>ISPOR Past President's Council</td>
<td>Leven (Seminar Suite)</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>ISPOR Portugal Chapter</td>
<td>Morar-Ness (Seminar Suite)</td>
</tr>
</tbody>
</table>
# Invitational Group Meetings

## TUESDAY, 7 NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-14:00</td>
<td>Lunch for delegates served in the Exhibit Poster Hall</td>
<td></td>
</tr>
<tr>
<td>7:30-10:00</td>
<td>ISPOR HTA Council</td>
<td>Ness (Seminar Suite)</td>
</tr>
<tr>
<td>7:45-8:45</td>
<td>ISPOR Patient-Centered Special Interest Group</td>
<td>Katrine (Seminar Suite)</td>
</tr>
<tr>
<td>8:45-9:45</td>
<td>ISPOR Austria Chapter</td>
<td>Alsh (Loch Suite)</td>
</tr>
<tr>
<td>8:45-9:45</td>
<td>ISPOR Italy-Rome Chapter</td>
<td>Dochart (Loch Suite)</td>
</tr>
<tr>
<td>12:00-13:45</td>
<td>ISPOR Optimization Task Force</td>
<td>Katrine (Seminar Suite)</td>
</tr>
<tr>
<td>12:00-14:00</td>
<td>ISPOR Student Network/Faculty Advisor Luncheon</td>
<td>Carron (Loch Suite)</td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>ISPOR CEE Consortium Executive Committee</td>
<td>Dochart (Loch Suite)</td>
</tr>
<tr>
<td>14:00-18:00</td>
<td>ISPOR Educational Forum: “Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as Evidence-Based Health Technology Assessment (HTA) specifically for Off-Patent Pharmaceuticals in Emerging Markets” (supported by an educational grant from Abbott)</td>
<td>Gallery Bistro (upstairs off the Mezzanine)</td>
</tr>
<tr>
<td>14:45-15:45</td>
<td>ISPOR ViHRI CEEWAA Editorial Board &amp; Editorial Advisory Board</td>
<td>Ness (Seminar Suite)</td>
</tr>
<tr>
<td>15:00-16:00</td>
<td>ISPOR Ukraine and Serbia Chapters</td>
<td>Alsh (Loch Suite)</td>
</tr>
<tr>
<td>15:15-16:45</td>
<td>ISPOR Stated Preference Research in EU Working Group</td>
<td>Katrine (Seminar Suite)</td>
</tr>
<tr>
<td>16:15-17:15</td>
<td>ISPOR Spain Chapter</td>
<td>Alsh (Loch Suite)</td>
</tr>
<tr>
<td>16:30-17:45</td>
<td>ISPOR Europe Chapters Presidents and EUPATI</td>
<td>Dochart (Loch Suite)</td>
</tr>
<tr>
<td>19:15-20:00</td>
<td>ISPOR Bulgaria Chapter</td>
<td>Carron (Loch Suite)</td>
</tr>
</tbody>
</table>

## WEDNESDAY, 8 NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45-13:45</td>
<td>Lunch for delegates served in the Exhibit Poster Hall</td>
<td></td>
</tr>
<tr>
<td>9:00-10:30</td>
<td>ISPOR Russia HTA Chapter</td>
<td>Dochart (Loch Suite)</td>
</tr>
</tbody>
</table>
**ISPOR Congress App**

Your meeting.
Your way.
In *your* pocket.

A simple, yet powerful, tool to get the most out of your ISPOR congress experience.

Search: ISPOR

**WI-FI NETWORK: ISPORGLASGOW**
**PASSWORD: IQVIA2017**

---

**Released Presentations**

*Looking for presentations from ISPOR Glasgow?*

[www.ispor.org » 20th Annual European Congress » Released Presentations](www.ispor.org » 20th Annual European Congress » Released Presentations)

Presentations are available online after each session, subject to speaker approval.

**Over 85% of presentations are expected to be available!**
## Research Poster Presentations Overview

Nearly 2200 poster presentations will be on display during the congress in the Poster and Exhibit Hall (Hall 4).

- The poster hall is organized in rows (A-N) and each poster board is numbered accordingly (e.g. A1, L15).
- Each poster presentation has been assigned a specific numbered board location, which is shown next to the poster presentation title. Please note that this is different than the poster code (e.g. PHP1, PCV5), which was assigned to each poster presentation upon acceptance.
- Poster presentation titles and authors, as well as the numbered board location, are available on the myISPORGlasgow.zerista.com web platform and mobile app. This information is also available as a PDF on the ISPOR website.
- An Author index is available in Value in Health 20 (9), which is available near ISPOR registration and online at [http://www.ispor.org/valueinhealth_index.asp](http://www.ispor.org/valueinhealth_index.asp).
- Poster board numbering is available on the floor plan on page 37 and row locations (by topic) are available in the table below.

<table>
<thead>
<tr>
<th>POSTER PRESENTATION SESSIONS</th>
<th>POSTER LOCATION</th>
<th>PRESENTER SET UP TIME</th>
<th>POSTER DISPLAY HOURS</th>
<th>AUTHOR DISCUSSION HOUR*</th>
<th>PRESENTER DISMANTLE TIME**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION I: MONDAY, 6 NOVEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCN: CANCER</td>
<td>ROWS A-L</td>
<td>8:30-8:45</td>
<td>8:45-13:45</td>
<td>12:45-13:45</td>
<td>13:45</td>
</tr>
<tr>
<td>PDB: DIABETES/ENDOCRINE DISORDERS</td>
<td>ROWS L-N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PUK: URINARY/KIDNEY DISORDERS</td>
<td>ROWS N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION II: MONDAY, 6 NOVEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHS: HEALTH SERVICES</td>
<td>ROWS A-F</td>
<td>15:30-15:45</td>
<td>15:45-19:30</td>
<td>18:30-19:30</td>
<td>19:30</td>
</tr>
<tr>
<td>PIH: INDIVIDUAL’S HEALTH</td>
<td>ROWS F-G</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMS: MUSCULAR-SKELETAL DISORDERS</td>
<td>ROWS G-J</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSY: SYSTEMIC DISORDERS/CONDITIONS</td>
<td>ROWS J-N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION III: TUESDAY, 7 NOVEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMD: MEDICAL DEVICES/DIAGNOSTICS</td>
<td>ROWS A-F</td>
<td>8:30-8:45</td>
<td>8:45-13:30</td>
<td>12:30-13:30</td>
<td>13:30</td>
</tr>
<tr>
<td>PCV: CARDIOVASCULAR DISORDERS</td>
<td>ROWS F-K</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGI: GASTROINTESTINAL DISORDERS</td>
<td>ROWS K-L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRS: RESPIRATORY-RELATED DISORDERS</td>
<td>ROWS L-N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION IV: TUESDAY, 7 NOVEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMH: MENTAL HEALTH</td>
<td>ROWS K-L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PND: NEUROLOGICAL DISORDERS</td>
<td>ROWS L-N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION V: WEDNESDAY, 8 NOVEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRM: RESEARCH ON METHODS</td>
<td>ROWS A-I</td>
<td>8:30-8:45</td>
<td>8:45-14:00</td>
<td>13:00-14:00</td>
<td>14:00</td>
</tr>
<tr>
<td>PIN: INFECTION</td>
<td>ROWS I-M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSS: SENSORY SYSTEMS DISORDERS</td>
<td>ROWS M-N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Presenters are required to be with their posters during the Poster Author Discussion Hour.

**Posters that are not removed at the scheduled dismantle times will be discarded.
Exhibit Program Overview

Exhibits Viewing
Exhibits will be on view in Hall 4.
Monday, 6 November: 8:30-19:45
Tuesday, 7 November: 8:30-19:15
Wednesday, 8 November: 8:30-14:15

Networking Lounges, Charging Stations, and Internet Stations
Please enjoy the various lounges, charging stations, and internet stations on the Exhibit floor.

New this year!
Business Café Sponsored by Complete HEOR Solutions (CHEORS)
Networking/Charging Lounge Sponsored by IQVIA

Internet stations are available in the front of Hall 4 at the Poster/Exhibit Look-Up Station.
Internet Access/Wi-Fi Sponsored by IQVIA

Schedule

SUNDAY, 5 NOVEMBER
8:00-18:00 Exhibitor Set Up

MONDAY, 6 NOVEMBER
8:30-19:45 Exhibits Viewing
10:45-11:15 Coffee Break
12:15-14:15 Lunch Sponsored by Health Economics and Outcomes Research Ltd
15:15-15:45 Coffee Break Sponsored by Ingress Health
18:00-19:45 Exhibitors’ Open House Reception Sponsored by Complete HEOR Solutions (CHEORS)

TUESDAY, 7 NOVEMBER
8:30-19:15 Exhibits Viewing
9:45-10:15 Coffee Break Sponsored by Covance
12:00-14:00 Lunch Sponsored by BaseCase Management GmbH
15:00-15:30 Coffee Break
17:45-19:15 Exhibitors’ Wine & Cheese Reception Sponsored by Pharmerit International

WEDNESDAY, 8 NOVEMBER
8:30-14:15 Exhibits Viewing
9:45-10:00 Coffee Break
12:45-14:15 Lunch
14:15 Exhibitor Dismantle
### Congress Exhibitors

<table>
<thead>
<tr>
<th>COMPANY NAME</th>
<th>EXHIBIT LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accession</td>
<td>801</td>
</tr>
<tr>
<td>Adelphi</td>
<td>301</td>
</tr>
<tr>
<td>Advanced Clinical Recruitment</td>
<td>202</td>
</tr>
<tr>
<td>Amaris</td>
<td>807</td>
</tr>
<tr>
<td>AMICULUM</td>
<td>Table #1</td>
</tr>
<tr>
<td>AMPLEXOR Life Sciences</td>
<td>109</td>
</tr>
<tr>
<td>Analysis Group</td>
<td>123</td>
</tr>
<tr>
<td>ANALYTICA LASER</td>
<td>703</td>
</tr>
<tr>
<td>AplusA</td>
<td>405</td>
</tr>
<tr>
<td>AXIS Consulting</td>
<td>505</td>
</tr>
<tr>
<td>Barrington James</td>
<td>212</td>
</tr>
<tr>
<td>BaseCase Management GmbH*</td>
<td>814</td>
</tr>
<tr>
<td>BresMed</td>
<td>501</td>
</tr>
<tr>
<td>Cardinal Health Specialty Solutions</td>
<td>811</td>
</tr>
<tr>
<td>Cochrane Innovations</td>
<td>Table #8</td>
</tr>
<tr>
<td>CEMKA</td>
<td>407</td>
</tr>
<tr>
<td>Complete HEOR Solutions (CHEORS)*</td>
<td>812</td>
</tr>
<tr>
<td>CONSULTING AT McCANN HEALTH</td>
<td>604</td>
</tr>
<tr>
<td>Context Matters</td>
<td>313</td>
</tr>
<tr>
<td>Costello Medical Consulting</td>
<td>316</td>
</tr>
<tr>
<td>Covance*</td>
<td>317</td>
</tr>
<tr>
<td>CRA, Charles River Associates</td>
<td>507</td>
</tr>
<tr>
<td>Creativ-Ceutical</td>
<td>213</td>
</tr>
<tr>
<td>CRECON Medical Assessment Inc.</td>
<td>406</td>
</tr>
<tr>
<td>Crystallise Ltd</td>
<td>Table #2</td>
</tr>
<tr>
<td>Curo</td>
<td>806</td>
</tr>
<tr>
<td>Decision Resources Group</td>
<td>403</td>
</tr>
<tr>
<td>Digital Health Outcomes &amp; GMAS</td>
<td>111</td>
</tr>
<tr>
<td>Dolon Ltd</td>
<td>118</td>
</tr>
<tr>
<td>Dymaxium</td>
<td>116</td>
</tr>
<tr>
<td>edemcareers</td>
<td>Table #10</td>
</tr>
<tr>
<td>EORTC</td>
<td>Table #7</td>
</tr>
<tr>
<td>Evidence Partners Inc.</td>
<td>119</td>
</tr>
<tr>
<td>Evidencia Scientific</td>
<td>808</td>
</tr>
<tr>
<td>Evidera*</td>
<td>601</td>
</tr>
<tr>
<td>Excerpta Medica</td>
<td>216</td>
</tr>
<tr>
<td>FACIT.org/FACITrans</td>
<td>117</td>
</tr>
<tr>
<td>GalbraithWight</td>
<td>209</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPANY NAME</th>
<th>EXHIBIT LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gareth Lee (G&amp;J Lee Recruitment)</td>
<td>Table #3</td>
</tr>
<tr>
<td>GfK</td>
<td>207</td>
</tr>
<tr>
<td>HealthCore, Inc.*</td>
<td>215</td>
</tr>
<tr>
<td>Health IQ</td>
<td>802</td>
</tr>
<tr>
<td>HEVA Group</td>
<td>221</td>
</tr>
<tr>
<td>HTA Consulting</td>
<td>309</td>
</tr>
<tr>
<td>ICON plc</td>
<td>503</td>
</tr>
<tr>
<td>IGES Group</td>
<td>122</td>
</tr>
<tr>
<td>INC Research/InVentiv Health</td>
<td>605</td>
</tr>
<tr>
<td>Ingress Health*</td>
<td>304</td>
</tr>
<tr>
<td>institute for Medical Technology Assessment (MTA)</td>
<td>203</td>
</tr>
<tr>
<td>INTEXO SRL</td>
<td>220</td>
</tr>
<tr>
<td>Ipsos Healthcare</td>
<td>120</td>
</tr>
<tr>
<td>IQVIA*</td>
<td>701</td>
</tr>
<tr>
<td>ISPOR</td>
<td>401</td>
</tr>
<tr>
<td>Journal of Health Economics and Outcomes Research</td>
<td>Table #4</td>
</tr>
<tr>
<td>Kantar Health</td>
<td>704</td>
</tr>
<tr>
<td>Lifescience Dynamics</td>
<td>311</td>
</tr>
<tr>
<td>Lightspeed Health</td>
<td>Table #9</td>
</tr>
<tr>
<td>MA Provider Srl</td>
<td>Table #5</td>
</tr>
<tr>
<td>MAESTRO Database</td>
<td>302</td>
</tr>
<tr>
<td>MAP BioPharma</td>
<td>103</td>
</tr>
<tr>
<td>Market Access Transformation</td>
<td>112</td>
</tr>
<tr>
<td>MINERVA Network</td>
<td>408</td>
</tr>
<tr>
<td>Mtech Access</td>
<td>303</td>
</tr>
<tr>
<td>Navigant</td>
<td>506</td>
</tr>
<tr>
<td>NEXTEP</td>
<td>115</td>
</tr>
<tr>
<td>Numerus</td>
<td>218</td>
</tr>
<tr>
<td>Open Health/pH Associates/OAC</td>
<td>105</td>
</tr>
<tr>
<td>Optum</td>
<td>211</td>
</tr>
<tr>
<td>Oxford PharmaGenesis</td>
<td>214</td>
</tr>
<tr>
<td>OXON EPIDEMIOLOGY</td>
<td>810</td>
</tr>
<tr>
<td>PAREXEL International</td>
<td>308</td>
</tr>
<tr>
<td>Patients Direct</td>
<td>110</td>
</tr>
<tr>
<td>Pharmatelligence</td>
<td>315</td>
</tr>
<tr>
<td>Pharmerit International*</td>
<td>813</td>
</tr>
<tr>
<td>PHARMO Institute</td>
<td>803</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPANY NAME</th>
<th>EXHIBIT LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHMR*</td>
<td>201</td>
</tr>
<tr>
<td>Pope Woodhead</td>
<td>306</td>
</tr>
<tr>
<td>PRA Health Sciences</td>
<td>307</td>
</tr>
<tr>
<td>Precision Health Economics (Part of Precision for Value)*</td>
<td>702</td>
</tr>
<tr>
<td>Prioris Ltd</td>
<td>602</td>
</tr>
<tr>
<td>PRMA Consulting</td>
<td>404</td>
</tr>
<tr>
<td>ProClinical</td>
<td>805</td>
</tr>
<tr>
<td>Quantify</td>
<td>210</td>
</tr>
<tr>
<td>Regulatory Pharma Net srl</td>
<td>114</td>
</tr>
<tr>
<td>Remap Consulting</td>
<td>205</td>
</tr>
<tr>
<td>R-Squared Talent Solutions</td>
<td>107</td>
</tr>
<tr>
<td>RTI Health Solutions</td>
<td>402</td>
</tr>
<tr>
<td>RWS Life Sciences</td>
<td>310</td>
</tr>
<tr>
<td>SchARR, University of Sheffield</td>
<td>314</td>
</tr>
<tr>
<td>SEC Recruitment</td>
<td>104</td>
</tr>
<tr>
<td>SIRIUS Market Access*</td>
<td>305</td>
</tr>
<tr>
<td>STATinMED Research</td>
<td>102</td>
</tr>
<tr>
<td>steve consultants</td>
<td>208</td>
</tr>
<tr>
<td>Synergus</td>
<td>108</td>
</tr>
<tr>
<td>Talentmark</td>
<td>Table #6</td>
</tr>
<tr>
<td>Taylor &amp; Francis</td>
<td>219</td>
</tr>
<tr>
<td>Tolley Health Economics Ltd.</td>
<td>121</td>
</tr>
<tr>
<td>TransPerfect</td>
<td>101</td>
</tr>
<tr>
<td>TreeAge Software</td>
<td>204</td>
</tr>
<tr>
<td>Truven Health Analytics, IBM Watson Health*</td>
<td>502</td>
</tr>
<tr>
<td>University of Glasgow</td>
<td>106</td>
</tr>
<tr>
<td>Valid Insight</td>
<td>217</td>
</tr>
<tr>
<td>ValueMAxess Ltd.</td>
<td>312</td>
</tr>
<tr>
<td>Vitaccess</td>
<td>804</td>
</tr>
<tr>
<td>Wickenstones</td>
<td>206</td>
</tr>
<tr>
<td>Wing Tech Inc.</td>
<td>113</td>
</tr>
<tr>
<td>Xcenda</td>
<td>603</td>
</tr>
<tr>
<td>York Health Economics Consortium</td>
<td>504</td>
</tr>
<tr>
<td>ZRx Outcomes Research Inc.</td>
<td>809</td>
</tr>
</tbody>
</table>

* Exhibitors who are also sponsors

Printed as of 13 October 2017
Exhibit/Poster Hall Floor Plan

Nearly 2200 poster presentations will be on display during the congress:
SESSION I: MONDAY, 6 NOVEMBER from 8:45-13:45
SESSION II: MONDAY, 6 NOVEMBER from 15:45-19:30
SESSION III: TUESDAY, 7 NOVEMBER from 8:45-13:30
SESSION IV: TUESDAY, 7 NOVEMBER from 15:30-19:15
SESSION V: WEDNESDAY, 8 NOVEMBER from 8:45-14:00

Exhibits will be on view:
Monday, 6 November from 8:30-19:45
Tuesday, 7 November from 8:30-19:15
Wednesday, 8 November from 8:30-14:15
PPI Healthcare Consulting

Adding global value through local expertise and insight

"Securing optimal market access for any medical technology, regardless of its novelty, is becoming increasingly difficult, requiring strategic planning and a thorough insight of stakeholders’ practices and expectations. PPI HC has been providing its clients with such insight and guidance since 2001 and would welcome the opportunity to assist you."

Adam Barak, Managing Director

Completed Country Assignments up to 2017:

EU5: 845
Other European countries: 495
North America: 46
South America: 30
Asia: 85

Pricing and Reimbursement (P&R) Consulting Services:

- Develop national/international pricing strategy throughout product planning process and post-launch
- Implementing and facilitating P&R submissions and revisions
- Direct stakeholder and secondary research to inform positioning and value demonstration strategies

Market Research Consulting Services:

- Market landscaping and segmentation
- Market access and payer research
- Product positioning, messaging
- Qualitative and quantitative research

Health Economic Consulting Services:

- Develop core and country-tailored value/submission dossiers
- Provide value and clinical evidence-generation needs including supportive studies design

For further information please contact PPI HC on:
Tel: +44 (0)2380 847891 Email: info@ppi.consulting Web: www.ppi.consulting
ISPOR 20th Annual European Congress
The Evolution of Value in Health Care

**Key Information**

**WiFi and Internet Access**
Internet stations are provided in the Exhibit-Poster Hall located in Hall 4. For the convenience of Congress attendees, Wi-Fi is available in the convention center. Network: ISPORGlasgow // Password: IQVIA2017
Wi-Fi is only intended for checking email and using the congress mobile app, not for downloading files. Connection speeds will vary depending on the volume of users.

**Internet/Wi-Fi Sponsored by IQVIA**

**Registration Disclaimer**
For security purposes all individuals must be registered and wear the official ISPOR Event Name Badge to gain access to the event, the sessions, the exhibit poster hall, and any other ISPOR activity. Onsite staff and security will monitor for name badges and will deny access if individual does not have an official ISPOR Event Name Badge. Individuals not wearing a name badge will be directed to registration. Please note that if you lose your name badge and need to have it re-printed you cannot print that at the self-serve station, you will need to visit the registration help desk.

Because of the professional nature of the program, safety and liability reasons; guests and anyone under the age of 18 are not permitted access or to register for the event. This includes access to the event in general, to scientific presentations, and to the exhibit and poster hall.

For any ISPOR sponsored social event, guests over the age of 21 are permitted to attend but must have a paid event ticket. Due to insurance and liability no one under 21 will be permitted to attend a social event.

**Language Information**
All sessions at the ISPOR 20th Annual European Congress are presented in English. ISPOR regrets that due to the disruption to other delegates, whisper translation (chuchotage) is not permitted in any session, including short courses. To discuss options to meet educational needs in multiple languages, please contact meetingsinfo@ispor.org.

**Presentation Slides/Posters**
Plenary session, issue panel, workshop, ISPOR forum, and symposia slides will be available via the congress app and at the ISPOR 20th Annual European Congress Released Presentations page at www.ispor.org during the congress, subject to speaker approval.
Podium and poster presentation abstracts and released slides or poster PDFs are available at the ISPOR Scientific Presentations Database (a searchable database of over 42,000 research papers presented at ISPOR meetings) at http://www.ispor.org/research_study_digests/index.asp.
The Released Presentations page will feature many of the congress’s slide presentations as PDFs. In 2016, more than 80% of the presentations were available to the public during the congress. The Released Presentations page is accessible via the congress mobile app and at www.ispor.org. 20th Annual European Congress.

**Speaker Information**
Upload the final version of your slide presentation in the Speaker Ready Room on the same day of your session.
All speakers are encouraged to use the Speaker Ready Room to preview their slide presentation and/or upload an updated version. Presentations submitted to ISPOR Speaker’s Corner by the specified advance deadline and all presentations uploaded/updated in the Speaker Ready Room 30 minutes prior to the session will be pre-loaded to the computer in the session room. All speakers are requested to arrive at their presentation room 15 minutes prior to the session start time. ISPOR staff will be available in the session room to assist the presenter.
A speaker ready room is provided in Fyne (Loch Suite) with the opening hours:
- Sunday, 5 November: 12:00-18:00
- Monday, 6 November: 8:00-18:00
- Tuesday, 7 November: 8:00-18:00
- Wednesday, 8 November: 8:00-15:30

ISPOR Research Presentation Awards

Awards are given for the best research presentations for podiums and posters in the categories of GENERAL, NEW INVESTIGATOR, and STUDENT (up to 3 in each category).
All research podium presentations are considered for an award. The top 10% of research poster presentations, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the Congress.
Award recipients will be notified by email and recognized on the ISPOR website at the conclusion of the congress.

**ISPOR Social Event: A Taste of Scotland**
Tuesday, 7 November 19:30-23:30
Merchant Square
Join us for whisky tasting, dinner, and traditional dancing and music.
The event takes place at Merchant Square, once part of the old Glasgow Fruit Market, in the heart of Glasgow.

**Guests will enjoy Scottish appetizers, whisky tasting, and have a choice of dinner options at the 5 restaurants within Merchant Square. A demonstration of Ceilidh dancing will be given and all will have the opportunity to participate in this easy-to-learn traditional dancing.**

Separate registration required. The price is £90 and includes transportation from the SEC to Merchant Square and back to the SEC, buffet dinner, 2 drinks, and entertainment. Registration subject to availability; see the ISPOR Registration desk for details.
- If you have pre-registered for the Social Event, your ticket will print out with your name badge. You will need this ticket for entry to the bus event.
- Buses will depart from the SEC between 19:30 and 20:00 for the 15-minute journey to Merchant Square.
- Return buses will start at 21:00, last bus at 23:15.

**Social Media**
Communicating by way of social media is encouraged if it falls within embargo and communications rules.
Be part of the live discussion!
- Tweet your comments to @ISPORorg during the congress using #ISPORGlasgow
- Access expert insights and share your views on congress sessions at the ISPOR LinkedIn Discussion Group: http://bit.ly/ISPOR-Ln
- Network with your peers on the ISPOR Facebook page: http://bit.ly/ISPOR-FB

**Recording and Press Information**
ISPOR supports the promotion of research presented at ISPOR congresses, while safeguarding sensitive information, data, and research findings that are not yet available to the public. Due to the sensitive nature of data and the particularly preliminary, unpublished research findings, all filming and recording of scientific sessions and the poster hall is prohibited during the congress, without the express written consent of ISPOR.

Portions of the ISPOR 20th Annual European Congress may be recorded by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). By participating in the discussions, congress registrants agree that ISPOR may electronically copy, videotape, or audiocapture their attendance at and involvement in any program. Registration and attendance at the ISPOR 20th Annual European Congress constitutes an agreement by the registrant to ISPOR’s use and distribution (both now and in the future) of their image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. ISPOR will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR.
Congress attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual’s scientific results. Members of the press must identify themselves as such before questioning speakers and congress attendees if using the information in a professional capacity. More detailed information on ISPOR’s Press Pass, Legal, and Embargo Policies are available on ISPOR’s News & Press page at the ISPOR website (www.ispor.org).

For further questions on these policies, please contact: Betsy Lane (blane@ispor.org), Director and Chief Marketing & Communications Officer.

**Congress Program Disclaimer**
Please be advised that while the congress program is designed to provide accurate information regarding the subject matter covered, the views, opinions, and recommendations expressed are those of the authors and speakers, not the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and thus ISPOR does not guarantee the accuracy of the information disseminated. If professional advice is desired, please consult a competent professional.

**Antitrust Compliance**
It is the undeviating policy of ISPOR to comply strictly with the letter and spirit of all local and U.S. Federal, State, and applicable international trade regulations and antitrust laws. Any activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or members that violate these regulations and laws are detrimental to the interests of ISPOR and are unequivocally contrary to ISPOR policy.

**Financial Disclosure Information**
Research podium and poster presentation financial disclosure information is available online at: http://www.ispor.org/valueinhealth_index.asp and in the October/November 2017 issue of Value in Health. Faculty and staff involved in the planning or presentation of this congress are required to disclose all real or apparent commercial financial affiliations related to congress content. This information is available on request at the ISPOR Registration desk.

**Questions & Information**
Please ask ISPOR staff members for any additional information about the congress or about ISPOR. ISPOR staff can be identified by their ISPOR name badge.

www.ispor.org | 39